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ABSTRACT 
DEVELOPMENT OF MACROMOLECULAR PRODRUG CONJUGATES FOR 
THE DIAGNOSIS AND TREATMENT OF MUSCULOSKELETAL DISEASES 
 
 Macromolecular prodrug conjugate is a promising strategy for better diagnosis 
and treatment of musculoskeletal diseases.  Our lab has pioneered this effort and 
has successfully developed multiple prodrug formulations.  The general approach 
we have taken is to incorporate active ingredient (AI, including imaging probe or 
therapeutic agents) containing monomers into water-soluble and biocompatible 
polymers, such as N-(2-Hydroxypropyl) methacrylamide (HPMA) copolymers.  
Structural parameters of these polymeric prodrugs, such as molecular weight 
(MW), drug loading, prodrug activation mechanism and the selection of drug pay-
load may greatly affect therapeutic efficacy and the safety of the macromolecular 
prodrugs.  To investigate the impact of these structural parameters in my research, 
(1) We have synthesized a series of the HPMA copolymer-based dexamethasone 
prodrugs with different molecular weight and drug loading.  After labeling with 125I 
or fluorescent dye, these prodrugs were administered to a murine implant loosen-
ing model.  The in vivo/ex vivo pharmacokinetics and biodistribution of these poly-
mers and in vitro and in vivo cellular internalization were analyzed and compared.  
(2) We designed and synthesized dexamethasone-containing monomers with dif-
ferent releasing chemistry and copolymerized with HPMA.  The different in vitro 
releasing rates of these prodrugs were confirmed.  When evaluated in an adjuvant 
induced arthritis rat model, these prodrugs demonstrated significantly different 
xiv 
 
therapeutic efficacy and duration.  (3) To understand if the design principle we 
learned from the dexamethasone prodrug can be extrapolated to other class of 
drugs, we replaced dexamethasone with Tofacitinib (Tofa, a disease-modifying an-
tirheumatic drug or DMARD) in the prodrug design.  The resulting prodrug (P-Tofa) 
was found to effectively ameliorate joint inflammation of the adjuvant-induced ar-
thritis rat model.  Collectively, the results from these systematic investigations pro-
vide us with more insight into the polymeric prodrug design principle and are 
instructive for the future development and clinical translation of the macromolecu-
lar prodrugs for musculoskeletal and other relevant diseases.  
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CHAPTER 1.  
 
INTRODUCTION 
 
1.1 Musculoskeletal Disorders  
 The musculoskeletal system is comprised of bones, muscles, cartilage, ten-
dons, and ligaments, as well as joints, and other connective tissues [1].  In addition 
to supporting the body, providing locomotion, the musculoskeletal system protects 
the vital soft tissue organs in the body and harbors hematopoietic tissues (in the 
bone marrow) and act as a reservoir for inorganic ions such as calcium and phos-
phorus [2].  The pathologic disorders of the musculoskeletal tissues affect large 
population of people, resulting in acute or chronic pain, loss of body motion, reduc-
tion of the life quality and even mortality.  The musculoskeletal diseases (MSD) 
show highly related with age, body weight (obesity) and work type.  Significant 
economic burden has been reported to be associated with MSD, which affects 
more than one out of every two persons in the United States age 18 and over, and 
nearly three out of four age 65 and over [3].  The rate of chronic musculoskeletal 
conditions found in the adult population is 76% greater than that of chronic circu-
latory diseases, which include coronary and heart conditions, and nearly twice that 
of all chronic respiratory conditions [4].  The diseases of the musculoskeletal cover 
a wide range of the pathological conditions, e.g., metabolic bone disorders (oste-
oporosis [5], Paget's disease [6], etc.); autoimmune diseases (rheumatoid arthritis, 
2 
 
systemic lupus erythematosus, etc.); degenerative joint disease (osteoarthritis); 
bone trauma or trauma-induced bone diseases (bone fracture, bone implant loos-
ening, trauma-induced heterotopic ossification) and bone cancers (osteosarcoma, 
bone metastasis), etc.  In this chapter, we will provide an overview of several MSD 
with high impact. 
1.2 Rheumatoid Arthritis 
 Rheumatoid arthritis (RA) is a chronic, inflammatory disorder that affects 0.8 
percent of adults worldwide and around 1 percent of adults in the United States [7, 
8].  The disease often leads to crippling pain associated with progressive articular 
cartilage damage and peri-articular bone erosion.  At present, there is no cure for 
RA [9, 10].   
 Multiple classes of medications have been developed for the treatment of RA 
patients.  Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, aspi-
rin, ketoprofen and naproxen have been shown to ease pain and inflammation 
associated with RA [11, 12] but they do not prevent joint damage and are often 
associated with significant gastrointestinal, renal [13] and cardiovascular side ef-
fects [14].  Glucocorticoids (GC) have been widely used to treat RA patients [13].  
Their long-term use, however, has been associated with serious side effects in-
cluding bone loss with increased incidence of fractures, infections, hypertension 
and cardiovascular complications, and diabetes mellitus [15, 16].  Disease-modi-
fying anti-rheumatic drugs (DMARDs), including methotrexate (MTX), sulfasala-
zine and leflunomide are currently being utilized to inhibit joint inflammation and 
3 
 
have been shown to impede joint destruction [17].  Multiple biological DMARDs, 
which selectively target proinflammatory cytokines or immunomodulatory path-
ways, have also been developed and shown to be clinically effective in suppress-
ing joint inflammation and attenuating joint destruction [18].  The identification of 
the key role of intracellular kinase signaling pathways in the regulation of proin-
flammatory cytokines and immune cell activation has led to the recent develop-
ment of orally available low molecular weight drugs that selectively target individual 
members of the Janus kinase pathway [19].  As an emerging class of medications, 
Janus kinase inhibitors (JAK inhibitors) offer new hope to RA patients who have 
experienced severe side effects or are refractory to current treatments [20].   
1.3 Particle-induced implant loosening 
 Total joint replacement is considered as an excellent surgery for improving the 
life quality for the patients who are suffering the end-stage of some musculoskel-
etal disorders, especially joint diseases such as osteoarthritis, inflammatory rheu-
matoid arthritis or the traumatic bone injury.  In 2011, 711,398 total knee 
replacements and 464,452 total hip replacements were performed.  The total cost 
was over 19 billion dollars [21].  10-20% of replaced joints, however, need to be 
revised within 10-20 years after arthroplasty due to the osteoclast-mediated peri-
implant osteolysis at the interface between bone and implant [22].   
 The aseptic implant loosening is considered as one of the main causation of 
the implant failure [23, 24], which is mainly induced by the granulomatous inflam-
matory reaction triggered by the wear-particle-activated macrophages [25-29].  
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Macrophages release prostaglandins, cytokines, metalloproteinases and lysoso-
mal enzymes (e.g. TNF-α, IL-1β, IL-6, and PGE-2) upon activation which initiate 
the bone resorbing pathways cascades [30, 31].   
 Commonly used imaging tools such as x-ray, computerized tomography (CT) 
and MRI in clinic have been used in the diagnosis of established bone loss of os-
teolysis and implant loosening.  These methods are very effective in detecting os-
teolysis and associated loss of implant fixation.  However, they only reveal 
anatomical changes within the limit of their imaging resolution, meaning when de-
finitive evidence of osteolysis is detected, considerable bone loss has already oc-
curred.  To better prevent the osteolysis, there is a critical need for a theranostic 
system that could both detect early wear particle-induced inflammatory events and 
in addition therapeutically target the inflammatory process and prevent incipient 
osteolysis.  Intervention at the early stage of inflammation would definitely prolong 
the life-time of the implant and improve long-term patient life quality.   
1.4 Heterotopic ossification 
 Though genetic mutation causing heterotopic ossification (HO) is rare with a 
prevalence around one of two million [32-35], HO is a common occurrence after 
multiple forms of extensive trauma, including arthroplasty [36-39], traumatic burn 
injury [40-43], and central nervous system (CNS) injury [44-47].  It has been re-
ported that the incidence rate of tHO is 10-20% in patients receiving arthroplasty 
[36], 0.1-3.3% in postburn patients [41], and 20%–30% in spinal cord injured pa-
tients [48].  The occurrence rate increases to as high as 63% following combat-
related amputation [49] and 60.1% in patients undergoing limb salvage [50].  The 
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cost of the treatment and prophylaxis of tHO varies depending on the severity, 
cause, and therapeutic methods [51-53].  tHO does not only induce severe perma-
nent pain [33], joint spasticity and autonomic dysreflexia [54, 55], but also causes 
increased pressure to the tissue under the tHO site leading to blood clot and deep 
vein thrombosis which affects blood circulation, possibly resulting in fatality [56].     
 tHO is a complex process that involves trauma, injury, and stimulations induc-
ing the activation of the inflammation cascade and differentiation of stem cells into 
chondrocytes and osteoblasts.  Severe systemic and stimulation-specific inflam-
mation evident by immediate elevated levels of inflammatory cytokines and ele-
vated injury severity score is associated with the development of tHO [57].  No 
single simple mechanism currently exists, although many common cellular mech-
anisms have been investigated within fibrodysplasia ossificans progressiva (FOP) 
and acquired forms of heterotopic ossification.  Several contributory factors have 
been suggested, including prostaglandin activity, specifically PGE-2, as well as 
hypercalcemia, tissue hypoxia, alterations in sympathetic nerve activity, prolonged 
immobilization and imbalances between parathyroid hormone activity and calci-
tonin [48].  With the discoveries relating cell phenotypes underlying tHO [58-64], 
the main cellular process of its development is attributed to the differentiation of 
endothelial-derived mesenchymal stem into chondrocytes and osteoblasts. The 
micro-environment also plays a role in tHO.  When stimulation in the soft tissue 
occurs, the inflammation starts to play its important precursor role in forming HO 
[65].  The local implantation that releases BMPs, part of the transforming growth 
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factor (TGF)-beta superfamily which are central to tissue homeostasis and osteo-
genesis, induces the formation of the acquired HO [66].  It has been deeply inves-
tigated in FOP, that the overactivation of activin receptor-like kinase-2 (ALK2), a 
type I BMP receptor, is the cause of the FOP.  The inhibition of the BMP receptor 
1-mediated BMP/SMAD pathway can therefore effectively inhibit HO [67].  
 The current treatment and prophylaxis for tHO usually include nonsteroidal anti-
inflammatory drugs (NSAIDs), radiotherapy, surgical excisions, and physical ther-
apy.  In the comparison trial studies, indomethacin showed superior therapeutic 
efficacy in preventing HO [68] formation compared to other NSAIDs; i.e. ibuprofen 
[69], aspirin [70], or other COX-2 selective NSAIDs [71-73].  However, side effects 
typically occur, such as the development of gastrointestinal hemorrhage [68], per-
forated ulcer [68], and non-selective inhibition of COX-1 leading to the reduction of 
thromboxane A2, which is essential to platelet aggregation [69].  Systemic admin-
istration of high-dose indomethacin and other NSAIDS for HO prophylaxis also 
leads to an imbalance of the formation and resorption of bone.  Irradiation therapy 
of bone growth and repair was first demonstrated in the 1950s [74], and was es-
tablished into HO prevention and proven to be effective after hip surgery in 1980s 
[75].  Currently, lower dose radiation therapy (RT) is used prophylactically pre- and 
post-operatively in patients with bone trauma or operative treatment [76, 77].  The 
potential side effects of RT also raise concern, however, such as radiation-induced 
carcinoma, bony nonunion, and azoospermia [78].  Bisphosphonate was approved 
from Food and Drug Administration (FDA) to treat tHO to reduce the hypercalcemia 
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and chemical absorb the calcium, however, limited because its GI toxicity and po-
tential to induce the hypocalcemia and induce the apoptosis of the osteoclast.  Sur-
gical excision is sometimes chosen by the patient when partially or completely 
restricted range of motion (ROM) is evident.  However, postoperative prophylaxis 
is still a reliable way to prevent new HO blast formation  [79].  Although the goal of 
physical therapy in patients with HO is to maintain the ROM and preserve function, 
the outcome is debatable, because of the passive stretching may cause micro-
trauma or local hemorrhage leading to inflammatory conditions [80].  Notably, the 
treatment of FOP not only includes what mentioned above, but also high-dose ad-
ministration of glucocorticoids to reduce lymphocytic infiltration and tissue edema 
and treat submandibular swelling [81].  Administration of dexamethasone in par-
ticular showed reduced ectopic calcification and limb impairment in ACVR1Q207D 
overexpressed mice versus vehicle-treated ACVR1Q207D overexpressed mice 
[67].  However, long-term use of corticoids has not been tested clinically due to the 
concern of its various side effects [67, 82, 83].   
 From these disease examples, we learned that the causes, treatments, medical 
interventions and financial burdens of different MSDs vary significantly.  However, 
the MSD also showed similarities, such like underlying inflammatory conditions, 
including angiogenesis, inflammatory cell infiltrations, bone, tendon or cartilage in-
volved, which gave the scientists more targets for the drug development strategy 
for the better therapeutic efficacy and reduced systemic off-target side effect. 
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1.5 Novel Nanomedicine for Treatment and Diagnosis of the Musculoskeletal Dis-
orders 
 Different from conventional pharmaceutical product, nanomedicine is a prom-
ising approach to offer targeted, sustained and controlled release of drugs at the 
musculoskeletal pathology.  To formulating nanomedicine, we shall understand the 
nature of the nanomedicine and the factors which will also influence the nanomed-
icine itself.  
1.5.1 Liposomes 
 Liposomes have been defined as a vehicle for drug delivery since the 1960s 
[84].  Liposomes are composed of spherical bilayer phospholipid membrane sur-
rounded aqueous core separated from the continuous aqueous solvent.  According 
to the number of lipid layers and the size of the liposomes, they can be categorized 
into multilamellar vesicle (MLV) [85], small unilamellar vesicle (SUV) [86] and large 
unilamellar vesicle (LUV) [87].  As drug delivery systems, liposomes have been 
applied to encapsulate both hydrophobic and hydrophilic drug. Besides its wide 
drug category loading capacity, liposomes delivery system can also protect the 
cargoes from enzymatic degradation or oxidation and enhance the intracellular up-
take.  To ensure their stealth against the mononuclear phagocyte system (MPS) 
liposome formulations can be decorated with inert water-soluble polymers (e.g., 
PEG, HPMA copolymer, etc.).  For certain purpose, targeting moieties or imaging 
probes can also be used to modify the surface of the liposomes.  The first FDA 
9 
 
approved nano-drug, liposomal-doxorubicin (also called Doxil or Lipodox or My-
ocet), was approved to use on the treatment of several cancer disease including 
the treatment of soft tissue sarcomas [88-90]. 
1.5.2 Micelles 
 Micelles are amphiphilic molecules consisted self-assembled colloidal systems, 
which can spontaneously aggregate into particles at a concentration higher than 
the critical micelle concentration (CMC).  The size and the shape of the micelle 
can varie from 10 nm to over 100 nm, spherical [91], ellipsoid cylindered, worm-
like or monolayer micelle [92].  A typical micelle has hydrophilic tails forming a shell 
structure, and the inner hydrophobic structure can encapsulate or conjugate with 
poorly water-soluble drugs.  This structure can be achieved using three types of 
the macromolecular drugs: 1. The molecule is composed of the one polar end (hy-
drophilic group) and one non-polar end (hydrophobic group) [93]. 2. Two polar 
ends with the non-polar center [91]. 3. Two non-polar ends with the polar center 
[94].  There are no FDA approved micellar drugs to treat MSDs now, however there 
are many researchers investigating on this type of nanomedicine [95].  Xu, et al. 
developed a conjugation system of sialic acid-dextran-octadecanoic acid (SA-Dex-
OA), which can self-assemble into micelle and load with the anti-rheumatic drug 
(methotrexate, MTX).  The significant higher bone mineral density in the adjuvant 
induced arthritis rats treated with MTX-loaded SA-Dex-OA micelles as compared 
to in those treated with free MTX and Dex-OA/MTX micelles may be contributed 
to not only the MTX prevention on bone erosion but also the effect of promoting 
MC3T3-E1 cell differentiation and mineralization by endogenous sialic acid [96].  
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Investigators, Low, et al. also cooperated the aspartic acid oligopeptides, which 
adsorb to hydroxyapatite, the mineral portion of bone, in their micelle formulation.  
The adsorption of this aspartic acid oligopeptides and hydroxyapatite is the strong-
est where bone turnover is highest or where hydroxyapatite is freshly exposed, 
such like in the condition of bone fracture.  The biodistribution study of this aspartic 
acid oligopeptides containing micelle conjugated with the 125I labeled anabolic 
agent, GSK3β Inhibitor showed a preferential accumulation of the micelle after a 
i.v. systemic injection to the fracture site in the murine model [97].  The improved 
fracture repair by this micellar drug and its branch derivative were shown in the 
same animal model [98].   
1.5.3 Nanoparticles 
 Nanoparticles can be categorized as drug nanoparticles, solid nanoparticles, 
polymer-based nanoparticles, lipid-based nanoparticles and nanocapsules.  Drug 
nanoparticles or so-called nanosuspension are dispersed water-insoluble drug 
particles in the nano-size range in an aqueous environment.  Drug nanoparticles 
can be achieved by breaking down the bigger particles by high-pressure homoge-
nization method or by special crystallization techniques.  Polymer-based nanopar-
ticles are commonly composed of poly(lactic acid) (PLA), poly(glycolicacid) (PGA), 
poly (lactic acid-co-glycolic acid) (PLGA), poly(ε-caprolactone) (PCL), and 
poly(methylmethacrylate) (PMMA).  Chemical synthesis, salting-out, emulsifica-
tion-diffusion, nanoprecipitation and freeze-drying methods are used to obtain pol-
ymer-based nanoparticles.  Lipid-based nanoparticles mostly composed of fats or 
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waxes and can be obtained by homogenization.  For certain applications, nano-
particles may be tailored into different shape, such as sphere nanoparticles [99], 
cube nanoparticles [100], rod-like nanoparticles [101], hollow spherical nanoparti-
cles [102] and random shape nanoparticles.  The use of the FDA approved nano-
particle drug or medical material used for the MSD conditions are mostly for the 
bone mimics, such like EquivaBone (Zimmer Biomet) [103], NanOss (RTI Surgical) 
[104], Ostim (Heraeus Kulzer) [105, 106], OsSatura (IsoTis Orthobiologics) [107], 
Vitoss (Stryker) [108].  These nanoparticles can provide a nanostructure with more 
surface area which allowed increased potential for cell attachment, and the simi-
larity to nature bone, which increases the potential to remodel into new bone.  Un-
der the same category of nanoparticles, there are a sub-category of the 
nanoparticles are approved by FDA to be used as the diagnostic tool, e.g. super-
paramagnetic nanoparticle, Magnevist, was approved by FDA as a contrast agent 
for magnetic resonance imaging to facilitate the visualization of lesions with abnor-
mal vascularity in the body [109].  
1.5.4 Dendrimers.  
 Dendrimers are highly uniformed, branched or star-shaped macromolecules. 
Dendrimers can be synthesized by divergent [110] or convergent approaches [111].  
They are often of uniform molecular weight and very low polydispersities.  Den-
drimers also have modifiable surface functional group as well as internal cavities 
[112].  For example, Newkome et al. [113] have synthesized a dendrimer contain-
ing hydrophobic interior and hydrophilic surface functionality.  During or after syn-
thesis of dendrimers, the drug molecules can be physically entrapped or 
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chemically conjugated to the dendrimer [114].  There are no FDA approved den-
drimer drug to treat MSDs, however, researchers has put efforts on developing the 
bone-targeting dendrimers such as Yamamoto group has developed aspartic acid 
conjugated PAMAM dendrimer or alendronate conjugated PAMAM dendrimer, 
those dendrimers showed strong targeting effect to the bone tissue [115, 116].  
When the alendronate conjugated dendrimer loaded with MTX and administrated 
to a bone metastasis murine model, the pharmacokinetics and therapeutic effect 
showed a preferential accumulation of the dendrimer to the bone tissue and a sig-
nificant lower cancer cells proliferated in the metastasis site.   
1.5.5 Macromolecular conjugates. 
 Macromolecular prodrug or polymeric conjugates which have a hydrodynamic 
diameter of less than 10 nm [117] may result in much less RES uptake and provide 
a better-controlled drug releasing profile by optimizing the covalent bond or linker 
between the drug and the carrier backbone.  Previously, in our lab, we have de-
veloped and tested a macromolecular theranostic system that has the capacity to 
detect early signs of wear particle-induced peri-implant granulomatous inflamma-
tion, and in addition to deliver potent anti-inflammatory and/or anti-bone resorptive 
agents specifically to the peri-implant tissues with minimal “off-target” side effects.  
Conceptually, this system is based upon our discovery that macromolecular 
theranostic agents can specifically target to sites of inflammation and undergo up-
take and activation by inflammatory cells [118, 119].  Besides HPMA conjugated 
macromolecular polymer drug, the PEGylated drug conjugates have also shown 
its promise in the drug delivery system development.  These conjugates have a 
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large population in the list of the approved of FDA approved nanomedicine, among 
which pegloticase (Krystexxa; Savient Pharmaceuticals), FDA approved 
PEGylated porcine-like uricase, showed a significant decrease of plasma uric acid 
level in about 40% of patients suffered with chronic gout (associated with a ten-
dency for tophi dissolution) [120].  The nanoformulation improved stability of pro-
tein through PEGylation, however, the targeting, retention and reduction 
immunogenic uricases of the drug still need to be developed since there were 
about 60% patients showed no change of their disease progression.   
 The great challenge for the development of the nanomedicine to treat or and 
diagnose the MSDs also remains a great opportunity for the researchers to de-
velop smarter and safer drug delivery systems and diagnostics.  These smarter 
and safer tools with the tropism to the MSD site may use different targeting strate-
gies. 
1.6 Targeting strategies 
 After choosing the delivery tool for drug, scientists made tremendous efforts to 
modify the delivery system to obtain a better targeting property to further enhance 
the therapeutic efficacy and reduce the off-target systemic toxicity.  Fortunately, 
MSDs have many unique features that can help nanomedicines differentiate the 
disease site with normal site and benefit them with a sustained retention. 
1.6.1 Passive targeting 
 In 1979, the antitumor protein drug neocarzinostatin (NCS) was conjugated 
with a synthetic copolymer of styrene maleic acid copolymer (SMA) which was 
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called SMANCS (molecular weight 16,000 g/mol) by Maeda [121].  This antitumor 
protein drug conjugate exhibited many unique properties, including prolonged half-
life in circulation (20-fold), improved tumor-targeting capacity (2000 fold intra-tu-
mor concentration than plasma), no immunogenicity and higher lipophilicity [122-
124].  These properties led to the conceptualization of the Enhanced Permeability 
and Retention effect (EPR effect) [125].  With the advantage of EPR effect, 
SMANCS became the first macromolecular anticancer drug approved in 1993 in 
Japan [122].  The EPR effect has been observed in the applications of many na-
nomedicine formulations, such as polymer conjugates, polymeric micelles and lip-
osomes [126, 127].  Most HPMA copolymers utilize the EPR effect to achieve 
better tumor targeting and delivery of drugs. EPR effect is a tumor vasculature-
dependent phenomenon.  Most tumors are well vascularized with high density and 
the rapid growth of blood vessels leads to irregular vascular alignment and defects 
of the junction between endothelial cells.  The increased local fenestration of mac-
romolecules paired with the ill-developed lymphatic drainage at the tumor lesion 
lead to the local accumulation of macromolecules over time [122, 128-132].  Wang 
et al. first described macromolecules’ Extravasation through Leaky Vasculature 
and their subsequent Inflammatory cell-mediated Sequestration (ELVIS) [133].  It 
explains the passive targeting of the HPMA copolymer–dexamethasone conjugate 
(P-Dex) to inflammations [134, 135].  Unlike the traditional understanding of EPR 
effect that macromolecules only can passively target to solid tumors (not inflam-
mation) due to the leaky vasculature and impaired lymphatic drainage, they found 
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although the extravasated macromolecules are cleared from the inflammatory tis-
sue quickly, rapid internalization by inflammatory infiltrates and locally activated 
cells provide the mechanism for the sustained retention of the macromolecular 
drug conjugate at the site of inflammation. 
1.6.2 Active targeting 
 The use of passive targeting mechanism is that researchers are taking the ad-
vantages of the nature of disease site, such like the EPR effect at tumor site and 
ELIVIS effect at inflammation site.  Different from this smart design, researchers 
also utilized many active targeting strategy to target and keep the drugs at the 
musculoskeletal sites.  Because of those unique features of the musculoskeletal 
system, we can design the drugs with the targeting moieties with higher affinities 
to those tissues. 
1.6.2.1 Bone targeting 
 Bone system is the hardest system in the body because of the needle-like crys-
tals composed by organic matrix and inorganic mineral phase of hydroxyapaptite 
(HA) [136].  Researchers choose to target the mineral composition (apatite) of the 
bone to obtain osteotropicity due to its biggest composition in bone and difficulties 
to target the organic matrix (such as the collagens which is ubiquitous in the body).  
There are many bone-targeting moieties can be utilized in the bone targeting drugs, 
including: 1. Tetracyclines have well-defined metal complexing abilities [137] and 
the nature of their chelation with surface calcium ions in bones [138]; 2. Pyrophos-
phate, bisphosphate, or alendronate can chelate the calcium ions because of their 
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phosphate structure [139], 3. Polymeric amino acid specific with certain sequence 
and abundance of the such amino acids like Asp, Glu, Gla or phosphorylated 
Ser/Thr can show the controlled nucleation capacity [2].  Some of those bone tar-
geting moieties have its own cellular medical or toxicity effect, ones need to pay 
much attention when conjugating them to the nanomedicine or nanodiagnostics.  
1.6.2.2 Tendon targeting 
 Unlike bone targeting, there is no many strategies for tendon targeting.  How-
ever, researchers have found that the muscle cells migration has its own direction 
which will end at the tendon tissue.  Tendon cells here are crucial in providing 
guidance for muscle migration by the formation of the complex between its type1 
transmembrane protein, which containing a leucine-richrepeat (LRR) domain in its 
extracellular region, and the Robo proteins in the muscle cells.  This natural cross-
communication with the existing targeting mechanism behind may inspire the drug 
delivery scientists in designing the drug to treat tendon disease [140]. 
1.6.2.3 Cartilage targeting 
 Drugs that can be injected intra-articular still face to another challenge that it is 
difficult to have enough drug penetrating into the cartilage tissue and reach the cell 
and matrix tissue.  This is not only because of the highly charged oligosaccharides 
introducing an effective polar barrier for penetration of lipophilic drug molecules, 
but also an intrinsic challenge results from the fact that low-molecular-weight so-
lutes in the joint will be eliminated due to the convective transport and lymphatic 
uptake.  Researchers have investigated using the addition of cationic domains or 
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proteins that favorable bind-to heparan sulfate or the glycosaminoglycan binding 
domain to obtain the longer retention at the intra-articular site and deeper penetra-
tion to the chondrocytes using the drug delivery carrier.   
 While the large amount of unmet medical needs of the drugs for the treatment 
and diagnosis of the musculoskeletal diseases remained, the nature of those types 
of diseases also provide the unique opportunities for the development and optimi-
zation of the targeted drug delivery system.  In the following chapters, we will in-
troduce our work on development of macromolecular prodrug conjugates for the 
diagnosis and treatment of musculoskeletal diseases. 
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CHAPTER 2 
DESIGN, SYNTHESIS AND CHARACTERIZATION OF MACROMOLECULAR 
PRODRUG WITH DIFFERENT MOLECULAR WEIGHT, DRUG COTENT, AND 
DRUG-CONTAINING MONOMER 
2.1 Introduction 
 As discussed in Chapter 1, to meet the clinical need for the treatment and early 
detection of the implant lossening, we have explored the potential utility of N-(2-
hydroxypropyl) methacrylamide (HPMA) copolymer conjugates as a theranostic 
platform for early diagnosis and prophylactic treatment of peri-prosthetic osteolysis. 
[118, 141].  Because of the nature of this synthetic, water-soluble polymer-based 
theranostic platform, structural parameters (such as average molecular weight 
(MW), drug loading, and the presence of active targeting ligands) are all known to 
have significant impact on the platform’s in vivo pharmacokinetic and biodistribu-
tion (PK/BD) profile.  In addition, the pathophysiology features (e.g., inflammation) 
may have a profound impact on the platform’s in vivo fate.  HPMA copolymer con-
jugates’ PK/BD profiles have been characterized in multiple animal models of hu-
man diseases. [142-144] In this chapter, we will focus on synthesizing a series of 
HPMA copolymers with different molecular weight (MW) and/or Dex contents 
which were labeled using Alexa Flour® 488, IRDye 800 CW, and radio isotope 125I 
respectively for the following in vitro and in vivo evaluation (Figure 2. 1); and HPMA 
copolymers with different Dex containing monomer (Figure 2. 2) to provide different 
releasing rates for the in vitro releasing characterization and in vivo therapeutic 
investigation. 
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Figure 2. 1 General structure of the HPMA copolymer conjugates. 
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Figure 2. 2 Chemical structure of different Dex containing monomer. 
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2.2 Materials and Methods 
2.2.1 Materials 
 N-(2-Hydroxypropyl) methacrylamide (HPMA), N-methacryloyl glycylglycyl hy-
drazinyl dexamethasone (MA-Dex), N-methacryloyl tyrosine amide (MA-Tyr-NH2), 
and S,S′-bis(α,α′-dimethyl-α″-acetic acid)-trithiocarbonate (CTA, purity >97%) 
were prepared as reported previously [145].  Sephadex LH-20 resin and PD-10 
columns were obtained from GE HealthCare (Piscataway, NJ). The Na125I was 
purchased from PerkinElmer (Waltham, MA).  IRDye 800CW NHS ester was pur-
chased from LI-COR, Inc. (Lincoln, NE).  Alexa Fluor® 488 NHS ester was pur-
chased from Life Technologies (Eugene, OR).  All other reagents and solvents 
were purchased from either Sigma-Aldrich (St. Louis, MO) or Acros Organics (Mor-
ris Plains, NJ).  All compounds were reagent grade or higher and used without 
further purification. 
2.2.2 Instruments 
 1H and 13C NMR spectra were recorded on a 500 MHz NMR spectrometer (Var-
ian, Palo Alto, CA).  A lambda 10 UV/vis Spectrometer (PerkinElmer, Waltham, 
MA) was used for UV/vis spectrophotometric analyses.  A ÄKTA Fast Protein Liq-
uid Chromatography system (FPLC, GE Healthcare Bio-Sciences, Pittsburgh, PA) 
equipped with Superdex 200 column, UV, and RI (KNAUER, Berlin, Germany) de-
tectors was used for analyses of P-Dex molecular weight.  HPLC analyses were 
performed on an Agilent 1100 HPLC system (Agilent Technologies, Inc., Santa 
Clara, CA) with a reverse phase C18 column (Agilent, 4.6 × 250 mm, 5 μm).  
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Zetasizer Nano ZS90 (Malvern, Worcestershire, UK) was used in P-Dex aggrega-
tion analyses. 
2.2.3 Synthesis of the macromolecular prodrugs with different molecular weight 
and drug content 
 The HPMA copolymer-dexamethasone conjugates were synthesized by a re-
versible addition−fragmentation chain transfer (RAFT) copolymerization as de-
scribed previously [146].  N-(2-Hydroxypropyl) methacrylamide (HPMA), N-
methacryloyl glycylglycyl hydrazinyl dexamethasone (MA-Dex), and N-methacry-
loyl tyrosine amide (MA-Tyr-NH2) were dissolved in anhydrous methanol and then 
copolymerized under argon at 45 °C for 48 h with 2,2″-azobis(isobutyronitrile) 
(AIBN) as an initiator and S,S′-bis(α,α′-dimethyl-α″-acetic acid) trithiocarbonate 
(CTA) as the RAFT agent.  The ratio of AIBN and CTA was adjusted to obtain 
HPMA copolymer-dexamethasone conjugates (P-Dex) with different molecular 
weight, and the dexamethasone (Dex) content was regulated by adjusting the MA-
Dex feed-in ratio (Table 2. 1).  The final tyrosine amide-containing HPMA copoly-
mer-Dex conjugates (P-Dex-Tyr-NH2) were obtained by lyophilization after the re-
moval of the unreacted low molecular weight compounds using LH-20 column. 
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P-Dex-15 kDa-12% 
 Molar ratio (%) Mw (g/mol) mmol mg 
HPMA 89.84 143.20 2.7933 400.00 
MA-Dex 6.41 588.70 0.1992 117.26 
AIBN 1.78 168.75 0.0554 9.35 
CTA 0.99 264.70 0.0308 8.14 
APMA 0.99 178.57 0.0306 5.47 
METHANOL 3.74 mL 
P-Dex-25 kDa-12% 
  Molar ratio (%) Mw (g/mol) mmol mg 
HPMA 91.05 143.20 2.7933 400.00 
MA-Dex 6.49 588.70 0.1992 117.26 
AIBN 0.94 168.75 0.0288 4.86 
CTA 0.52 264.70 0.0160 4.24 
APMA 1.00 178.57 0.0306 5.47 
METHANOL 3.74 mL  
P-Dex-35 kDa-12% 
 Molar ratio (%) Mw (g/mol) mmol mg 
HPMA 91.48 143.20 2.7933 400.00 
MA-Dex 6.48 588.70 0.1979 116.49 
AIBN 0.67 168.75 0.0206 3.47 
CTA 0.37 264.70 0.0114 3.03 
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APMA 1.00 178.57 0.0304 5.44 
METHANOL 3.74 mL 
P-Dex-45 kDa-12% 
 Molar ratio (%) Mw (g/mol) mmol mg 
HPMA 91.64 143.20 2.7933 400.00 
MA-Dex 6.49 588.70 0.1979 116.49 
AIBN 0.56 168.75 0.0171 2.89 
CTA 0.31 264.70 0.0095 2.52 
APMA 1.00 178.57 0.0304 5.44 
METHANOL 3.74 mL 
P-Dex-20 kDa-12% 
 Molar ratio (%) Mw (g/mol) mmol mg 
HPMA 89.40 143.20 2.7933 400.00 
MA-Dex 6.50 588.70 0.2031 119.57 
AIBN 2.00 168.75 0.0623 10.24 
CTA 1.11 264.70 0.0346 9.78 
MA-Tyr-NH2 1.00 248.30 0.0312 7.76 
METHANOL 3.74 mL 
P-Dex-30 kDa-12% 
 Molar ratio (%) Mw (g/mol) mmol mg 
HPMA 90.93 143.20 2.7933 400.00 
MA-Dex 6.50 588.70 0.1997 117.55 
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AIBN 1.01 168.75 0.0311 5.10 
CTA 0.56 264.70 0.0173 4.87 
APMA 1.00 248.30 0.0307 7.63 
METHANOL 3.74 mL 
P-Dex-40 kDa-12% 
 Molar ratio (%) Mw (g/mol) mmol mg 
HPMA 91.45 143.20 2.7933 400.00 
MA-Dex 6.50 588.70 0.1985 116.88 
AIBN 0.68 168.75 0.0207 3.40 
CTA 0.38 264.70 0.0115 3.24 
MA-Tyr-NH2 1.00 248.30 0.0305 7.58 
METHANOL 3.74 mL 
P-Dex-30 kDa-6% 
 Molar ratio (%) Mw (g/mol) mmol mg 
HPMA 94.31 143.20 3.4916 500.00 
MA-Dex 3.25 588.70 0.1203 70.83 
AIBN 0.93 168.75 0.0343 5.62 
CTA 0.51 264.70 0.0190 5.37 
APMA 1.00 248.30 0.0370 9.19 
METHANOL 4.15 mL 
P-Dex-30 kDa-0% 
 Molar ratio (%) Mw (g/mol) mmol mg 
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HPMA 97.69 143.20 3.4916 500.00 
MA-Dex 0.00 588.70 0.0000 0.00 
AIBN 0.84 168.75 0.0300 4.93 
CTA 0.47 264.70 0.0167 4.66 
APMA 1.00 248.30 0.0357 8.87 
METHANOL 4.15 mL 
Table 2. 1 Feed-in ratio of the AIBN, CTA, HPMA and MA-Dex, was adjusted to 
obtain HPMA copolymer-dexamethasone conjugates (P-Dex) with different molec-
ular weight, and the dexamethasone (Dex) content. 
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2.2.4 Synthesis of 125I labeled P-Dex (P-Dex-125I) 
 To label the P-Dex-Tyr-NH2 with 125I, the tyrosine containing copolymers (∼1 
mg) were dissolved in saline (50 μL, 0.9%) in a glass vial (1 mL).  Chloramine-T 
(100 μL, 4.8 mg/mL, saline) and NaI125 solution (pH = 12, 20 μL, 1 mCi) were 
sequentially added to the solution.  This reaction was stirred at room temperature 
(0.5 h) and quenched by Na2S2O3 (6 mg/mL, in 100 μL saline).  After purification 
by PD-10 column, twice, the resulting solution (1.5 mL) was obtained with strong 
radioactivity (∼0.08−0.12 mCi).  The entire labeling process was done according 
to a protocol approved by the University of Nebraska Medical Center Radiation 
Safety Office in a fume hood with face velocity of 100 FPM and with lead shield 
protection.  Post labeling cleaning and contamination survey were performed to 
ensure the absence of any radiation contamination in the working area. 
2.2.5 Synthesis of IRDye 800CW-labeled P-Dex (P-Dex-IRDye) 
 P-Dex-APMA (the copolymers of HPMA and N-(3-aminopropyl) methacryla-
mide,10 50 mg, containing ∼0.0037 mmol of amine) and IRDye 800CW NHS ester 
(1.25 mg, 0.001075 mmol LI-COR Biosciences, Lincoln, NE) were dissolved in di-
methylformamide (DMF, 900 μL) with 15 μL of N,N-diisopropylethylamine (DIPEA) 
added.  The solution was stirred overnight in darkness at room temperature. The 
product was then purified on an LH-20 column and lyophilized.  The IRDye 800CW 
content was determined using Lambda 10 UV/vis Spectrometer. 
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2.2.6 Synthesis of Alexa Fluor® 488 labeled P-Dex (P-Dex-Alexa) 
 P-Dex-APMA (50.0 mg, containing ∼0.0037 mmol of amine) and Alexa Fluor 
488 NHS ester (0.75 mg, 0.001 mmol, Life Technologies, Eugene, OR) dissolved 
in DMF (900 μL) with DIPEA (15 μL) added.  The mixture was stirred overnight in 
darkness at room temperature.  The product was then purified on an LH-20 column 
and lyophilized.  The Alexa Fluor 488 content was determined using a Lambda 10 
UV/vis Spectrometer. 
2.2.7 Synthesis of HPMA copolymer conjugates with different Dex-containing 
monomer (P-Dex-A, P-Dex-B, P-Dex-C, P-Dex-D) 
2.2.7.1 Synthesis of Monomer A 
 As shown in Figure 2.3,dexamethasone and imidazole were dissolved in anhy-
drous DMF and the solution was cooled to 0 °C by ice bath.  TBSCl was added.  
The solution was stirred at 0 °C for 1h and then allowed to room temperature for 
3h.  Ethyl acetate (200 ml) was added and the solution was then washed with 
saturated brine.  The organic phase was then dried over Na2SO4 and then the 
solvent was removed to get crude product 1. 
 The crude product was then dissolved in a solution of hydrazine monohydrate 
in methanol, and then acetic acid was added.  The solution was stirred at room 
temperature for 4h.  Ethyl acetate was added and the solution was then washed 
with saturated brine.  The organic phase was then dried over Na2SO4 and then the 
solvent was removed to get the residue.  Flash column chromatography to give 
product 2.  Some compound 1 was recovered.   
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 N-(3-aminopropyl)methacrylamide hydrochloride and Et3N were dissolved in 
anhydrous DMF at 0 °C.  Mono-methyl terephthalate and DCC were then added.  
The solution was stirred at room temperature for 6h.  Ethyl acetate was added and 
the solution was then washed with saturated brine.  The organic phase was then 
dried over Na2SO4 and then the solvent was removed.  The residue was purified 
by column chromatography to give product 3. 
 Compound 3 was dissolved in a mixture of water and methanol, KOH was then 
added.  The solution was stirred at room temperature overnight.  HCl solution was 
added to neutralize the KOH.  Ethyl acetate was used to extract the product from 
the aqueous phase.  Then the solvent was removed, the residue was purified by 
flash chromatography to give the product 4. 
 Compound 2, DCC, HOBt and DIPEA were dissolved in anhydrous DMF, then 
compound 4 was added.  The solution was stirred at room temperature 3h.  Ethyl 
acetate was added and the solution was then washed with saturated brine.  The 
organic phase was then dried over Na2SO4 and then the solvent was removed.  
The residue was purified by column chromatography to give product 5. 
 Compound 5 was dissolved in THF and TBAF (1M, THF) was added.  The 
solution was stirred at room temperature for 1h.  Ethyl acetate was added and the 
solution was then washed with saturated brine.  The organic phase was then dried 
over Na2SO4 and then the solvent was removed.  The residue was purified by 
column chromatography to give product 6 (Monomer A). 
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Figure 2.3 Synthesis route of Monomer A. 
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2.2.7.2 Synthesis of Monomer B 
 As shown in Figure 2.4 compound 2 and methyl bromoacetate were dissolved 
in anhydrous DMF, potassium carbonate was then added to the solution.  The 
solution was heated to 80°C for 2h.  Ethyl acetate was added and the solution was 
then washed with saturated brine.  The organic phase was then dried over Na2SO4 
and then the solvent was removed.  The residue was purified by column chroma-
tography to give product 7. 
 Compound 7 and 1,3-diaminopropane were dissolved in MeOH.  The solution 
was stirred at room temperature overnight.  Ethyl acetate was added and the so-
lution was then washed with saturated brine.  The organic phase was then dried 
over Na2SO4 and then the solvent was removed to give the crude product 8. 
 The crude compound 8 and triethylamine were dissolved in dichloromethane. 
The solution was then cooled to 0°C with ice-water bath.  The methacryl chloride 
in dichloromethane was added dropwise.  After addition, the solution was then 
stirred 1 hour at 0°C for 1h.  Ethyl acetate was added and the solution was then 
washed with saturated brine.  The organic phase was then dried over Na2SO4 and 
then the solvent was removed.  The residue was purified by column chromatog-
raphy to give product 9. 
 Compound 9 was dissolved in THF and TBAF (1M, THF) was added.  The 
solution was stirred at room temperature for 1h.  Ethyl acetate was added and the 
solution was then washed with saturated brine.  The organic phase was then dried 
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over Na2SO4 and then the solvent was removed.  The residue was purified by 
column chromatography to give product 10 (Monomer B). 
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Figure 2. 4 Synthesis route of Monomer B 
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2.2.7.3 Synthesis of Monomer C 
 As shown in Figure 2.5, the isomer of compound 2 is a byproduct of the reaction 
of preparing compound 2.  It was dissolved in anhydrous DMF with DCC.  The 
solution was cooled to 0°C with ice-water bath and then added MA-Gly-Gly-OH 
and DMAP.  The solution was stirred at 0°C for 3h.  Ethyl acetate was added and 
the solution was then washed with saturated brine.  The organic phase was then 
dried over Na2SO4 and then the solvent was removed.  The residue was purified 
by column chromatography to give product 11. 
 Compound 11 was dissolved in THF and TBAF (1M, THF) was added.  The 
solution was stirred at room temperature for 1h.  Ethyl acetate was added and the 
solution was then washed with saturated brine.  The organic phase was then dried 
over Na2SO4 and then the solvent was removed.  The residue was purified by 
column chromatography to give product 12 (Monomer C). 
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Figure 2. 5 Synthesis route of Monomer C 
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2.2.7.4 Synthesis of Monomer D 
 To get Monomer D, dexamethasone, DMAP and triethylamine were dissolved 
in anhydrous dichloromethane.  The solution was cooled to 0°C with ice-water bath 
and then methacryl chloride in dichloromethane was added dropwise.  The solution 
was then stirred 1 hour at 0°C for 1h.  Ethyl acetate was added and the solution 
was then washed with saturated brine.  The organic phase was dried over Na2SO4 
and the solvent was removed.  The residue was purified by column chromatog-
raphy to give product 13 (Monomer D, shown in Figure 2.6). 
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Figure 2. 6 Synthesis route of Monomer D 
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2.2.8 Characterization of the HPMA copolymer conjugates 
 Size exclusion chromatography (SEC) with an ÄKTA fast protein liquid chro-
matography (FPLC) system was used to determine the number-average molecular 
weight (Mn), weight-average molecular weight (Mw), and the polydispersity index 
(PDI) of the copolymers using a calibration of HPMA homopolymers with narrow 
PDI.  To quantify Dex content in P-Dex, the copolymers were hydrolyzed in 0.1 N 
HCl (1 mg/ mL) overnight.  The resulting solution was neutralized and analyzed on 
an Agilent 1100 high performance liquid chromatography (HPLC) system with a 
reverse phase C18 column (Agilent, 4.6 × 250 mm, 5 μm).  Mobile phase, acetoni-
trile/water 2:3; detection, UV 240 nm; flow rate, 1 mL/ min; injection volume, 10 μL.  
The analyses were performed in triplicate.  The mean value and standard deviation 
were obtained using Excel.  The characterizations of all HPMA copolymer conju-
gates used in this study are summarized in Tables 2.2 and 2.3.  The potential 
aggregation of the P-Dex (6 wt%) was characterized by DLS with a series of con-
centrations.  Three measurements at each concentration were performed, and the 
results were averaged and summarized in Table 2.5.  
 The Dex content analysis of the HPMA copolymer with different Dex-containing 
monomers is as similar as described above.  The weight average molecular weight 
(Mw), number of molecular weight (Mn) polydispersity (PDI) and Rayleigh Ratio 
(RΘ, dn/dc) of the P-Dex-A, P-Dex-B, P-Dex-C, and P-Dex-D were analyzed using 
a combination of AKTÄ pure FPLC system, Wyatt multiangle light scattering sys-
tem and Optilab T-rEX refractive index concentration detector.  In vitro releasing 
profile of the P-Dex (for a clear comparison, we named P-Dex as P-Dex-E in all 
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the following study related with the different releasing rate polymers evaluation), 
P-Dex-A, P-Dex-B, P-Dex-C, and P-Dex-D was conducted in different pH buffered 
solution (pH 5.0 acetate buffer, pH 6.0 acetate buffer, pH 7.0, pH7.4 and pH 8.7 
phosphate buffer, pH 11 sodium carbonate buffer, human serum and rat serum).  
The copolymers were weighted and dissolved in to different buffer to the concen-
tration of 4 mg/mL (polymer/solution) with Pluronic F127 (1 wt% of total Dex) added 
to create the “sink” condition.  The copolymer-containing solutions were then fixed 
into a shaking incubator (60 r/min) at 37 °C.  At pre-designed time points, the re-
leasing solutions were withdrawn, neutralized and then extracted with 9 times in 
volume of METB.  The 1/3 volume of METB was then withdrawn and evaporated 
using vacuum evaporator. (eg. 50 uL samples released in pH 4.5 solution was 
withdrawn and neutralized using 6.5 uL pH 10 solution.  Then 508.5 uL METB was 
added for extraction and 169.5 uL METB supernatant was withdrawn followed with 
the solvent evaporated using vacuum evaporator.  The residues were resus-
pended into 100 uL H2O/MeOH solution (H2O/MeOH=1:9) for HPLC injection).  
The HPLC analyses was based on the standard curve using dexamethasone base 
under the same flowing condition to determine the free Dex concentration.  The 
METB extraction recovery rate was analyzed using the same method in the in vitro 
releasing part within the Dex concentration from 5-500 µg/mL. 
2.3 Results 
2.3.1 Characterization of HPMA copolymer conjugates 
 The synthesis of all the HPMA copolymer-dexamethasone conjugates and their 
labeling with 125I and fluorescent labels were straightforward [146].  By employing 
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RAFT copolymerization, we were able to control the MW of the HPMA copolymer 
conjugates and manage their PDI in a narrow range as shown in Tables 2.2 and 
2.3.  The dynamic light scattering analysis results of P-Dex copolymers with differ-
ent MW and Dex content were presented in Table 2.4 and results for P-Dex-35 
kDa-6% at different concentration can be seen in Table 2.5. The DLS data clearly 
suggest that P-Dex-35 kDa-6% forms aggregates under the conditions tested. This 
finding may partially explain the unexpected fast clearance of P-Dex-35 kDa-6% 
found in the PK/BD study.  
 The HPMA copolymer conjugates with different monomers were characterized 
as described above.  The results shown in Table 2.6 represented the MW and PDI 
of the polymers were as designed.  The relatively low drug content in the P-Dex-B 
may be the result of the potential releasing of the Dex from the fast releasing 
monomer B during the polymerization.  
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Polymer 
conjugates 
Mw 
(× 103 
g/mol) 
PDI 
Dex content 
(μmol/g) 
Radioactivity 
(μCi/g) 
P-Dex-20 kDa-12% 20.5 1.11 283.09 ± 35.16 138.8 
P-Dex-30 kDa-12% 30.7 1.18 346.28 ± 10.70 394.8 
P-Dex-40 kDa-12% 39.1 1.21 341.94 ± 25.98 354.8 
P-Dex-30 kDa-6% 35.3 1.17 170.46 ± 22.42 200.4 
P-Dex-30 kDa-0% 30.8 1.06 0 180.8 
Table 2.2 The characterization of HPMA copolymer conjugates labeled with 125I. 
Mw: weight average molecular weight; PDI: polydispersity index. 
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Polymer 
conjugates 
Mw 
(×103 
g/mol) 
PDI 
Dex Content 
(μmol/g) 
[Alexa 488] 
(μmol/g) 
[IRDye 
800CW] 
(μmol/g) 
P-Dex-15 kDa-12% 15.9 1.35 306.55 ± 27.24 10.89 ± 0.15 6.20 ± 0.14 
P-Dex-25 kDa-12% 27.5 1.4 300.13 ± 11.23 13.82 ± 0.27 6.08 ± 0.31 
P-Dex-35 kDa-12% 35.3 1.49 356.34 ± 39.55 10.25 ± 0.20 7.89 ± 0.04 
P-Dex-45 kDa-12% 45.3 1.34 315.32 ± 18.40 12.63 ± 1.28 7.55 ± 0.14 
P-Dex-35 kDa-6% 35.7 1.29 168.86 ± 20.33 11.83 ± 0.38 7.54 ± 0.10 
P-Dex-35 kDa-0% 36.0 1.45 0 13.50 ± 0.30 7.83 ± 0.11 
Table 2.3 The characterization of HPMA copolymer conjugates labeled with fluo-
rescent probes. Mw: weight average molecular weight; PDI: polydispersity index; 
Dexamethasone content; [Alexa-488]: Alexa Fluor® 488 content; [IRDye-800CW]: 
IRDye 800CW content. 
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Sample 
Name 
P-Dex-15  
kDa-12% 
P-Dex-35  
kDa-12% 
P-Dex-45  
kDa-12% 
P-Dex-35  
kDa-6% 
P-Dex-35  
kDa-0% 
Z-Ave 
(d.nm) 
6.643 7.673 8.552 163.9 6.828 
PDI 0.237 0.318 0.209 0.481 0.174 
Table 2.4 Result of dynamic light scattering characterization of polymers at a 
concentration of 5 mg/mL. Z-Ave: Z-Average size (diameter.nm); PDI: Polydisper-
sity index. 
  
44 
 
Concentration 
(mg/mL) 
5 37.5   150  
Z-Ave (d.nm) 163.9 282.9 313.6 
PDI 0.481 0.769 1 
Table 2.5 Result of dynamic light scattering characterization of P-Dex-35 kDa-6% 
at different concentration. Z-Ave: Z-Average size (diameter. nm); PDI: Polydisper-
sity index. 
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Polymer 
conjugates 
Mw 
(×103 g/mol) 
PDI Dex Content (μmol/g) 
P-Dex-A 35.8 1.32 329.76 ± 8.80 
P-Dex-B 36.7 1.36 113.61 ± 13.19 
P-Dex-C 35.4 1.13 418.27 ± 12.63 
P-Dex-D 31.9 1.48 303.66 ± 9.22 
P-Dex-E 39.1 1.23 258.11 ± 6.40 
Table 2.6 The characterization of HPMA copolymer conjugates conjugated with 
different Dex-containing monomers. Mw: weight average molecular weight; PDI: 
polydispersity index. 
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2.3.2 In Vitro release profile of the P-Dex-A, P-Dex-B, P-Dex-C, P-Dex-D, P-Dex-
E in different releasing buffer 
 The in vitro Dex release was studied by incubating P-Dex-A, P-Dex-B, P-Dex-
C, P-Dex-D, P-Dex-E in pH 5.0, pH 6.0, pH 7.0, pH 7.4, pH 8.7, pH 11.0, human 
serum and rat serum at 37°C (Figure 2.7).  The polymers all showed different re-
leasing rates in different buffers.  When comparing the rates under the same buffer, 
different polymers released with differently rates. The releasing rates sequence 
also changed when the buffer changed (Figure 2.8).  For example, under acidic 
condition, pH 4.5 and pH 5.5, the releasing rate trend was RP-Dex-B > RP-Dex-C > RP-
Dex-D > RP-Dex-E > RP-Dex-A.  Under biological PBS buffer (pH 7.4) the releasing rate 
trend was RP-Dex-D > RP-Dex-B > RP-Dex-C > RP-Dex > RP-Dex-A.  Under basic condition 
(pH 10), considering the self-degradation of Dex, the releasing rate trend in the 
first 3 days was used to compare: RP-Dex-D > RP-Dex-C > RP-Dex-B > RP-Dex-A > RP-Dex.  
The recovery rate was 97.18 ± 2.6% 
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Figure 2.7 In Vitro Dex release from P-Dex P-Dex-A, P-Dex-B, P-Dex-C, P-Dex-D, 
P-Dex-E.  The polymers showed different releasing rates under different pH. Each 
sample was measured three times.  The mean values and standard deviation were 
calculated using GraphPad Prism 7.   
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Figure 2.8 In Vitro Dex release from P-Dex P-Dex-A, P-Dex-B, P-Dex-C, P-Dex-D, 
P-Dex-E at different releasing solution (pH=5.0, 6.5, 7.0, 7.4, 8.7 and 11, human 
serum and rat serum).  Each sample was measured three times.  The mean values 
and standard deviation were calculated using GraphPad Prism 7.  
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2.4 Discussion  
 The passive targeting of nanomedicines, including water-soluble macromole-
cules after systemic administration, has been validated in multiple animal models 
of inflammatory diseases, which encompass chronic systemic autoimmune disor-
ders (e.g., rheumatoid arthritis, systemic lupus), acute local injuries (e.g., fracture), 
and chronic local inflammatory conditions (e.g., peri-implant osteolysis) [119, 146-
148].  We posited that the mechanism for this passive targeting is different from 
the enhanced permeability and retention (EPR) effect [149] and may be explained 
by an ELVIS mechanism (Extravasation through Leaky Vasculature and Inflamma-
tory cell-mediated Sequestration) [134, 150, 151], in which the systemically admin-
istered nanomedicine would extravasate through the leaky vasculature at the 
inflammatory lesion and be sequestered locally via inflammatory cell infiltrates and 
activated resident cell.  Concurrently, for systemic inflammatory conditions, a frac-
tion of the nanomedicine administered may also be sequestered by white blood 
cells (WBC) in the circulation and be actively transported to the inflammatory lesion.  
Previously, we have found that the HPMA copolymers’ structural parameters, such 
as average MW and drug loading, have a significant impact on their pharmacoki-
netic and biodistribution (PK/BD) profile in a systemic inflammatory arthritis rat 
model[144].  The focus of this and the next chapter, therefore, is to define the 
impact of MW and drug loading on PK/BD profile of HPMA copolymer-dexame-
thasone conjugates in a model of localized inflammation. For this purpose, we syn-
thesized a series of HPMA copolymers with different MW or Dex content as 
described above.  Using both 125I-labeling/gamma counter techniques and the NIR 
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optical imaging, we would validate the impact of MW and Dex content on the 
PK/BD profiles of HPMA copolymers in the mouse model of aseptic implant loos-
ening in the following chapter. 
 Besides molecular weight and drug content, the chemical structure of the Dex 
containing monomer will also affect the conjugates’ pharmacokinetics since it will 
affect the drug releasing property.  To better understand the influence of the poly-
mer properties on the biology system, and to further instruct the future drug devel-
opment, the designation and synthesis of polymers with different Dex containing 
polymers were of high value.  With a low drug loading of the P-Dex-B, it was ex-
cluded from the in vivo evaluation, with the consideration of the drug content shall 
be similar when comparing with the other polymers to avoid multiple factors in the 
same experiment.  The results from in vivo therapeutic of those different monomers 
containing polymers would be compared in this chapter and following chapters.   
2.5 Conclusion 
 In this chapter, we designed and synthesized a series of the HPMA copolymers 
with different structural parameters.  The HPMA copolymers with different molec-
ular weight (MW) and/or Dex contents were labeled using Alexa Flour® 488, IRDye 
800 CW, and radio isotope 125I respectively.  Different Dex containing monomers 
were designed, synthesized and polymerized with HPMA to form different HPMA-
Dex-copolymers with different Dex releasing rates.  The conjugates were charac-
terized for their molecular weight, polydispersity, labeling content, and in vitro re-
leasing rate.   
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CHAPTER 3 
PK/BD ANALYSIS AND IN VITRO INTERNALIZATION ANALYSIS OF 
MACROMOLECULAR PRODRUG WITH DIFFERENT MOLECULAR WEIGHT, 
DRUG COTENT IN THE ASEPTIC IMPLANT LOOSENING MOUSE MODEL 
3.1 Introduction 
 As discussed in Chapter 1, we would focus on elucidating the impact of different 
structural parameters on HPMA copolymer conjugates’ PK/BD profile in an aseptic 
orthopedic implant loosening mouse model.  The results from the study of this 
chapter will help identify the optimal structural design of the HPMA copolymer-
based theranostic platform for early diagnosis and prophylactic treatment of peri-
prosthetic osteolysis, respectively.  We would try to develop a novel theranostic 
strategy for early diagnosis and effective treatment of peri-implant orthopedic wear 
particle-induced osteolysis by systematically manipulating the structural parame-
ters of the system to optimize its extravasation/lymphatic clearance, cellular uptake, 
partitioning and drug release using the novel intraosseous femoral implant mouse 
model. 
3.2 Materials and Methods  
3.2.1 Materials 
 Ten-week-old male CD 1 IGS mice were purchased from Charles River Labor-
atories and maintained under standard housing conditions.  All animal experiments 
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were performed in accordance with protocols evaluated and approved by the In-
stitutional Animal Care and Use Committee (IACUC) of the University of Nebraska 
Medical Center. 
3.2.2 Instruments 
 Isoflurane vaporizer (Midmark Corp, Dayton, OH) was used to anesthetize an-
imals during live imaging analyses.  A Faxitron MX-20 Cabinet X-ray System (Fax-
itron Bioptics, Tucson, AZ) was used in the implant loosening model establishment 
to confirm the implant position.  A Packard Cobra II Gamma Counter (PerkinElmer, 
Waltham, MA) was used in the tissue radioactivity counting in the gamma counter-
based PK/BD study.  A Pearl Impulse small animal imaging system (LI-COR, Lin-
coln, NE) was used for near-infrared (NIR) optical imaging of live animals.  Flow 
cytometry on disaggregated cells was performed on a BD LSRII flow cytometer 
(BD Biosciences, San Jose, CA) and on BD FACS Scan and BD FACS Canto 
cytometers for the in vitro uptake studies. 
3.2.2 Establishment of a murine prosthesis failure model 
 A murine prosthesis failure model was established surgically as we described 
previously [141].  Poly(methyl methacrylate) (PMMA) particles (1−10 μm, Bangs 
Laboratories, Fishers, IN) were used to induce the peri-prosthetic inflammation.  
The position of the implant was validated with Faxitron MX-20 Cabinet X-ray Sys-
tem. Mice were administrated antibiotics (cefazolin sodium, 20 mg/kg, s.c.) imme-
diately after surgery, and analgesics (buprenorphine, 0.5 mg/kg, s.c.) were given 
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twice daily for 3 days after surgery.  Biweekly intraarticular injection of PMMA par-
ticles (1 mg in 10 μL sterile saline) into the left knee joint was done postoperatively 
to mimic the gradual particle releasing process in the patients.  Saline of similar 
volume was injected into the right knee as the control.  A total of 180 male CD 1 
IGS mice were used in the gamma counter-based PK/BD analysis experiment, and 
25 mice were used for the NIR imaging-based PK/BD analysis.  
3.2.3 Gamma counter-based pharmacokinetic and biodistribution analysis 
 On 30th day post implant introduction, 125I-labeled and unlabeled P-Dex-Tyr-
NH2 conjugates (∼1.5 μCi/mice, 5 mg polymer/mice) were mixed and administered 
to mice (5 mice/group) via tail vein injection.  Animals were sacrificed at designated 
time points (0.5, 2, 6, 16, 48, 168 h).  Blood and other major organs/tissues includ-
ing, heart, lungs, kidneys, liver, spleen, and both hind limbs were isolated at eu-
thanasia.  They were processed and analyzed using a Packard Cobra II Gamma 
Counter without perfusion.  The pharmacokinetic parameters, such as total clear-
ance (CL), the volume of distribution (Vd), and biological half-life (t1/2) were deter-
mined using the bolus intravenous input noncompartmental analysis of WinNonlin 
(version 6.3, Pharsight, Mountain View, CA).  The area under the curve (AUC) was 
calculated using the trapezoidal rule.  The relative exposure ratio was calculated 
by dividing AUCtissue by AUCblood. AUClast from both tissues and blood was used for 
the relative exposure ratio. 
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3.2.4 Near-infrared optical imaging analysis 
 On the 30th day post implant introduction, mice were given P-Dex- IRDye (0.3 
mg/mice) via tail vein injection (5 mice/group).  The mice were imaged at desig-
nated time points (0.5, 24, 48, 72, 96, 120, 144, 168 h) using a Pearl Impulse small 
animal imaging system to evaluate the distribution and retention of the IRDye-la-
beled prodrug.  All mice were anesthetized with 2% isoflurane throughout proce-
dures and dehaired before imaging. Imaging acquisition condition is dual channel 
(800 nm and white light) with 85 μm resolution.  Images for each mouse were 
normalized using the same intensity scale with a common minimum and maximum 
value.  The signal intensity from the left joints was semiquantitatively analyzed by 
the resident software (Pearl Impulse Software).  The regions of interest (ROI) with 
identical areas were selected manually as a 59 × 59 (pixels) ellipse shape using a 
drawing tool in the software at both knee joints and background (Figure 3.1).  The 
center of the ROI was located to the knee joint manually.  Signal intensity of the 
knee joint minus background signal intensity was then corrected for the area (pix-
els).  Although the fluorescence dye content was controlled similar when synthe-
sized, to compare with the signals from animals receiving different conjugates, a 
signal standardization method was developed as follows: conjugate solutions (20 
μL, 3 mg/mL) were dropped on a Petri dish and imaged at the same imaging con-
ditions (Figure 3.1A).  The signals from the droplets were analyzed using the same 
method described above.  The signal from the left knee joint was corrected accord-
ing to the signal intensity obtained from conjugates droplets images in Figure 3.1A 
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in order to eliminate the impact of different dye content in the conjugates during 
the in vivo imaging analysis.  The equation is listed below: 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑧𝑒𝑑 𝑀𝑒𝑎𝑛 𝑆𝑖𝑔𝑛𝑎𝑙 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 (%) =
𝐼𝐿 −𝐼𝐵
𝐼𝑖 − 𝐼𝐵𝑖
20𝜇𝐿 × 3𝑚𝑔 𝑚𝐿⁄
× 5𝑚𝑔
× 100% 
where IL is mean signal intensity from left knee ROI, IB is mean signal intensity 
from background, Ii is mean signal intensity from initial droplet, and IBi is mean 
signal intensity from background in initial droplet image. 
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Figure 3.1 Near infrared imaging analysis of mice with systemic administration of 
P-Dex-IRDye conjugates. A. Images of conjugate solution drops (20 µL, 3 g/mL). 
The percentage represents the Dex content in each polymer conjugate tested. The 
circled areas identify representative regions of the ROI and background selected 
for analyses. 
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3.2.5 Fluorescence-activated cell scanning (FACS) analysis 
 The FACS analysis procedure was adapted from previous work [118].  Two 
days after the last intraarticular particle injection, the mice were given P-Dex-Alexa 
488 (5 mg/mouse) via tail vein injection.  At necropsy (24 h post injection), the left 
femurs were isolated and minced aseptically. The tissues were further digested 
with type IA collagenase (1 mg/mL, Sigma- Aldrich) at 37 °C for 30 min twice.  After 
passing through a 70 μm cell strainer, ACK Lysing Buffer (Quality Biological, 
Gaithersburg, MD) was then used to remove the red blood cells. After centrifuga-
tion (1200 rpm, 5 min), a single cell suspension (1 × 106 cells/50 μL) was obtained. 
For FACS evaluation of dendritic cells, macrophage, monocytes, and fibroblast 
cells, the samples were incubated with the following antibodies: hamster anti-
mouse CD11c (BD Biosciences, Pharmingen), Allophycocyanin (APC)-labeled rat 
antimouse F4/80 (eBioscience, San Diego, CA), APC-labeled rat antimouse Ly-
6G (Gr-1, Gr1) (eBioscience, San Diego, CA), and Alexa Fluoro 647 labeled rabbit 
antimouse P4HB (Abcam, Cambridge, MA), respectively, for 30 min on ice. Cells 
incubated with hamster antimouse CD11c were further treated with Alexa Fluoro 
647-labeled goat antihamster secondary antibody for another 30 min on ice.  All 
the cells were then fixed in FACS fixation buffer and stored at 4 °C prior to analyses 
on a BD LSR II flow cytometer. 
3.2.6 In Vitro internalization study of HPMA copolymer conjugates in macrophages.  
 To evaluate the internalization of HPMA copolymer conjugates in vitro, fluores-
cence microscopy and flow cytometry were used to conduct these studies.  
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3.2.6.1 Fluorescence microscope imaging.  
 Primary BMMs were prepared by conventional procedures and plated onto 
glass coverslips at a density of 2.5 × 105 cells per well of a 12-well plate in alpha-
MEM medium supplemented with 10% fetal bovine serum and 25 ng/mL M-CSF.  
After overnight incubation, copolymers were added from a 20 mg/mL stock in PBS 
to a final concentration of 40 μg/mL.  After additional 24 or 48 h incubation, cells 
were washed with HBSS, labeled with Hoechst 33342 (2 μg/mL for 5 min in HBSS), 
fixed with 2% paraformaldehyde for 15 min at 37 °C, washed with HBSS, and 
mounted using ProLong Gold Antifade mounting medium.  Cells were imaged, and 
captured images were analyzed using a Nikon Eclipse fluorescence microscope. 
3.2.6.2 Flow cytometric analysis.  
 Primary BMMs were prepared by conventional procedures and plated in alpha-
MEM Petri dishes (one million cells in 8 mL per dish).  After overnight incubation, 
polymers were added from a 20 mg/mL stock in PBS to a final concentration of 40 
μg/mL.  After additional incubation 4−48 h, cells were washed with PBS, tryp-
sinized, washed again, and resuspended in 0.6 mL of stain buffer (BD Pharmigen).  
Cells were stained with a 7-AAD viability stain prior to flow cytometric analysis on 
FACScan or FACScanto cytometers. 
60 
 
3.3 Results  
3.3.1 The pharmacokinetics and biodistribution of the HPMA copolymer conju-
gates in the peri-implant osteolysis mouse model 
3.3.1.1 Gamma counter-based PK/BD analyses of HPMA copolymer conjugates 
in the peri-implant osteolysis mouse model using 125I-labled conjugates 
 The percentage of injected conjugate dose per gram (ID/g) of tissue vs time 
(0.5, 2, 6, 16, 48, and 168 h postinjection) in all major organs, blood, and both 
femurs are shown in Figure 3.2.  For P-Dex with different MWs but the same Dex 
content (∼12 wt %), MW clearly had a major impact on the distribution of P-Dex 
conjugates in major organs.  Of all the conjugates tested, P-Dex-40 kDa-12%, 
which has the highest MW, showed the maximum ID/g value in most of the organs 
examined at the earliest time points. In the kidney, however, the conjugate with the 
lowest MW (P-Dex-20 kDa-12%) was found with the highest ID/g values at the end 
point. While all other conjugates examined exhibited a biphasic clearance pattern, 
PDex-40 kDa-12%’s clearance showed a unique pattern.  Increased ID/g values 
were found for P-Dex-40 kDa-12% during 2−6 h postinjection in all tissue and or-
gans, during 16−48 h in the liver and both femurs, and during 48−168 h in the 
spleen. Increased ID/g values were also found in both femurs and spleen during 
2−6 h postinjection with P-Dex-30 kDa-0%.  In all organs and tissues, P-Dex-30 
kDa-6% showed the lowest ID/g at every time point.  The difference between the 
PMMA particle-injected left femur and nonparticle-injected right femur were not 
significant with all of the tested polymer conjugates, which is contrary to our previ-
ous findings [118].  
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Figure 3.2 The pharmacokinetics profiles of HPMA copolymer conjugates with dif-
ferent molecular weights and Dex contents in blood and major organs/tissues over 
the time course of 7 days post i.v. administration.  n=5.  
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3.3.1.2 Biodistribution of HPMA copolymer conjugates in tissues according to 
the live optical imaging 
 Due to the insensitivity of gamma counter-based PK/BD analysis techniques in 
defining the differential distribution pattern of P-Dex conjugates between the femur 
with peri-implant osteolysis and the control, we performed additional analyses us-
ing P-Dex conjugates labeled with IRDye 800CW.  As shown in Figure 3.3, this 
approach confirmed the critical role of MW in determining the PK/BD profile. The 
retention time of the P-Dex in vivo increased with an increase in MW.  Unlike the 
gamma counter-based PK/BD study, live NIR optical imaging permitted discrimi-
nation of the peri-implant inflammation site from the control site.  The fluorescent 
signal intensity from left knee (with implant and particle infusion) increased with 
the increase of MW at the same time point post i.v. administration.  When the signal 
from the knee joint was corrected as described in the equation in the methods 
section, the semiquantitative results (Figure 3.5) corroborate well with the visual 
observation.  In Figure 3.4, the P-Dex-30 kDa-6% showed an unexpected PK/BD 
profile, comparing with all the other groups.  The fast elimination of the conjugate 
was evidenced by the low signal from the mice after 48-h post-injection.  This result 
was in agreement with the gamma counter-based PK/BD experiment finding using 
P-Dex-125I. 
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Figure 3.3 Representative NIR optical images of mice with femur implants chal-
lenged with PMMA particles on left femur and PBS on the contralateral side.  Im-
ages were obtained 0.5, 24, 48, 72, 96, 120, 144, and 168 h after one intravenous 
injection of P-Dex-IRDye conjugates (Dex content ∼12 wt %, with different MW).  
Pseudo color-coded signal intensity reflects the level of polymers within the mice.  
The signal intensity was normalized using the same intensity scale for each image. 
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Figure 3.4 Representative NIR optical images of mice with femur implants chal-
lenged with PMMA particles on left femur and PBS on the contralateral side.  Im-
ages were obtained 0.5, 24, 48, 72, 96, 120, 144, and 168 h after one intravenous 
injection of P-Dex (MW ~ 35 kDa, with different Dex content) at designed time 
points.  Pseudo color-coded signal intensity reflects the level of polymers within 
the mice.  The signal intensity was normalized using the same intensity scale for 
each image. 
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Figure 3.5 Semi-quantitative analysis of the image signals gained from optical im-
age system. 
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3.3.2 Gamma counter-based pharmacokinetic analyses 
 PK parameters of the tested conjugates in blood and major organs/tissues were 
obtained using a noncompartmental analysis (Table 3.1).  Systemic exposure as 
expressed by AUC and MRT increased with increasing MW. For example, AUC of 
PDex- 40 kDa-12% was ∼26-fold higher than P-Dex-20 kDa-12%. Both Vd and Cl 
decreased with increasing MW, but the decrease in Cl was more pronounced, 
which leads to the overall increase in exposure as measured by AUC and MRT.  
Also the low Cl associated with higher MW formulation (P-Dex-40 kDa- 12%) led 
to the longer half-life of 35.8 h.  Increasing the MW increased exposure of blood, 
as well as all other tissues as measured by AUC and MRT. Dex loading also af-
fected the MRT and AUC.  For example, P-Dex-30 kDa-0% had ∼3-fold higher 
AUC0‑∞ than P-Dex-30 kDa-6%, and Cl of P-Dex-30 kDa-6% was ∼3-fold higher 
than P-Dex-30 kDa-0%; while PDex-30 kDa-12% had ∼2-fold higher AUC0‑∞ than 
P-Dex-30 kDa-6%, and Cl of P-Dex-30 kDa-6% was 2-fold higher than PDex- 30 
kDa-12%. 
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Parame-
ters (unit) 
P-Dex-20 
kDa-12% 
P-Dex-30 
kDa-12% 
P-Dex-40 
kDa-12% 
P-Dex-30 
kDa-6% 
P-Dex-30 
kDa-0% 
t1/2 (hr) 27.4 ± 5.9 22.3 ± 6.6 35.8 ± 3.7 23.9 ± 3.5 24.3 ± 4.7 
Cl 
(mL/hr/kg) 
316.9 ± 
19.1 
115.7 ± 
10.6 
12.5 ± 0.9 
238.6 ± 
11.6 
73.9 ± 3.8 
Vss(mL/kg) 
6,473.5 ± 
301.6 
1,850.6 ± 
274.2 
516.4 ± 
77.7 
4,225.1 ± 
516.2 
1,332.2 ± 
154.3 
AUC0- 
(blood) (hr* 
count/gm) 
376,071.8 
± 22102.0 
1,057,256.
4 ± 
103135.1 
10,134,744
.0 ± 
732647.0 
520,626.4 
± 24637.4 
1,682,399.
0 ± 
86933.0 
AUC (% 
extrapola-
tion) 
1.1 ± 0.5 1.3 ± 1.5 4.2 ± 1.4 0.6 ± 0.3 0.7 ± 0.4 
AUCleft fe-
mur/AUCbood 
0.34 0.38 0.23 0.43 0.39 
AUCright fe-
mur/AUCbood 
0.33 0.35 0.23 0.49 0.41 
AUCheart/A
UCbood 
0.67 0.71 0.49 0.74 0.64 
AUCliver 
/AUCbood 
1.43 1.1 0.8 1.36 0.84 
AUCspleen/A
UCbood 
0.64 0.52 0.42 0.45 0.43 
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AUClungs/A
UCbood 
1.1 0.92 0.60 0.98 0.85 
AUCkid-
ney/AUCbood 
6.02 1.6 0.57 2.32 0.77 
MRT0- 
(blood) (hr) 
20.4 ± 0.6 16.1 ± 2.8 41.4 ± 5.9 17.7 ± 2.2 18.0 ± 1.3 
MRTleft fe-
mur/MRTbood 
2.94 3.57 2.58 3.74 4.34 
MRTright fe-
mur/MRTbood 
2.97 3.54 2.44 3.43 4.33 
MRTheart/M
RTbood 
2.64 3.36 2.03 3.29 3.30 
MRTliver 
/MRTbood 
4.06 4.09 2.38 3.83 3.68 
MRTspleen/
MRTbood 
4.54 4.21 2.43 3.37 3.83 
MRTlungs/M
RTbood 
2.88 4.29 1.70 3.08 3.85 
MRTkid-
ney/MRTbood 
2.42 3.06 1.70 2.94 2.93 
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Table 3.1 The pharmacokinetic (PK) parameters of different HPMA copolymer con-
jugates after systemic administration. t1/2, the half-life associated with the elimina-
tion phase; CL, total body clearance; Vss, volume of distribution in steady state; 
AUC, area under a concentration of analyte vs time curve. 
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3.3.3 In Vivo fluorescence-activated cell scanning (FACS) analysis 
 For all the tested cell phenotypes (CD11c+, F4/80+, Ly-6G (Gr-1, Gr1)+, and 
P4HB+, see Figure 3.6), the percentage of cells that internalized the P-Dex copol-
ymers increased with the increase of the MW of the polymers (e.g., PDex-15 kDa-
12%, P-Dex-35 kDa-12%, and P-Dex-45 kDa-12%).  This increase was highly sig-
nificant when the MW was raised from 15 to 35 kDa.  For instance, the percentage 
of CD11c positive cell increased from 41.67% to 89.28% when treated with P-Dex-
15 kDa-12% and P-Dex-35 kDa-12%, respectively.  The difference in the percent-
age of the cells that internalized the polymers was not significant, however, when 
MW was raised from 35 to 45 kDa.  The Dex content also affected the cell uptake 
of P-Dex copolymers. With the increase of Dex content, the percentage of the cells 
that internalized the P-Dex copolymers was also increased for several of the cell 
phenotypes tested in this study (see Table 3.2).  As shown in Figure 3.7, over 90% 
of the cell-sequestered P-Dex-Alexa were found in Ly-6G (Gr-1, Gr1) positive cells.  
The cell uptake efficiency increased with the increases of P-Dex MW.  The impact 
the Dex content has on cell internalization efficiency was more complex.  For ex-
ample, more P-Dex with higher Dex content was sequestrated by F4/80 positive 
cell, while more P-Dex with lower Dex content was sequestered by Ly-6G (Gr-1, 
Gr1) positive cells (see Table 3.3). 
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Figure 3.6 Percentage of different cell phenotypes isolated from peri-implant region 
that internalized different HPMA copolymers-Dex conjugate.  Except for those 
noted as not significant (ns, P > 0.05), all the other paired group comparisons are 
statistically significant (P < 0.05). 
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Figure 3.7 Percentage of P-Dex-Alexa internalized by different cell phenotypes 
isolated from peri-implant region.  Except for those noted as not significant (ns, P > 
0.05), all the other paired group comparisons are statistically significant (P < 0.05).  
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Polymer 
P-Dex-15  
kDa-12% 
P-Dex-35  
kDa-12% 
P-Dex-45  
kDa-12% 
P-Dex-35  
kDa-6% 
P-Dex-35  
kDa-0% 
CD11c+ 41.67 89.28 81.98 62.63 57.53 
F4/80+ 34.01 83.85 80.09 65.22 64.19 
Ly6G+ 18.99 93.94 94.16 62.38 50.20 
P4HB 38.61 81.75 72.79 54.008 57.77 
Table 3.2 The percentage of different cell phenotypes that internalized P-Dex-
Alexa at the peri-implant region. 
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Polymer 
P-Dex-15  
kDa-12% 
P-Dex-35  
kDa-12% 
P-Dex-45  
kDa-12% 
P-Dex-35  
kDa-6% 
P-Dex-35  
kDa-0% 
CD11c+ 6.70 3.76 2.19 2.12 3.50 
F4/80+ 9.75 8.07 8.70 9.10 4.26 
Ly6G+ 97.07 96.26 91.40 98.61 98.45 
P4HB 9.37 5.83 2.81 3.18 3.09 
Table 3.3 The percentage of P-Dex-Alexa being sequestered by different cell phe-
notypes at the peri-implant region. 
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3.3.4 Impact of Structural Parameters on in Vitro BMM Internalization P-Dex.  
 To determine the effect of MW on cellular uptake of the HPMA copolymer con-
jugates, murine BMMs were incubated with Alexa-488 labeled P-Dex with Dex 
content ∼12 wt % and different MW (ranging from 15 kDa to 45 kDa).  Cells were 
analyzed using flow cytometry and fluorescence microscopy at 4, 24, and 48 h 
after addition of the copolymers to the cells.  The flow cytometric data (Figure 3.8) 
revealed that all four of these copolymers were taken up by the BMMs, being de-
tectable at 4 h and increasing throughout the time course. MW did not appear to 
have any significant effects on copolymer uptake since the kinetics and levels of 
uptake were very similar between the four copolymers.  To determine the effect of 
Dex content on uptake of HPMA copolymers by BMMs, three copolymers of similar 
MW (∼35 kDa), but differing Dex content were analyzed by flow cytometry and 
fluorescence microscopy as described above. 
 Flow cytometry revealed that the kinetics and levels of uptake of the P-Dex 35 
kDa-6 wt % and P-Dex 35 kDa-12 wt % conjugates were indistinguishable (Figures 
3.9 and 3.10).  Uptake of the dexamethasone-free copolymer appeared somewhat 
higher than that of the dexamethasone-containing copolymers, which may in part 
be due to the relatively higher loading of Alexa Fluor 488 on this copolymer. 
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Figure 3.8 In vitro flow cytometry analysis of murine BMM internalization of P-Dex 
with different molecular weight (Dex content ~12 wt %, labeled with Alexa Fluor 
488).  
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Figure 3.9 In vitro flow cytometry analysis of murine BMM internalization of P-Dex 
with different Dex content (MW ~ 35 kDa, labeled with Alexa Fluor 488). 
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Figure 3.10 In vitro fluorescence microscope analysis of murine BMM internaliza-
tion of P-Dex (MW ~ 35 kDa, with different Dex content), 20×, scale bar = 50 μm. 
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3.3.5 Dynamic Light Scattering Analysis of P-Dex 
 The dynamic light scattering analysis results of different P-Dex copolymers are 
presented in Table 3.4 and results for P-Dex-35 kDa-6% at different concentration 
can be seen in Table 3.5.  The DLS data clearly suggests that P-Dex-35 kDa-6% 
forms aggregates under the conditions tested. This finding may partially explain 
the unexpected fast clearance of P-Dex-35 kDa-6% found in the PK/BD study. 
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Sample 
Name 
P-Dex-15  
kDa-12% 
P-Dex-35  
kDa-12% 
P-Dex-45  
kDa-12% 
P-Dex-35  
kDa-6% 
P-Dex-35  
kDa-0% 
Z-Ave 
(d.nm) 
6.643 7.673 8.552 163.9 6.828 
PDI 0.237 0.318 0.209 0.481 0.174 
Table 3.4 Dynamic light scattering (DLS) analysis of copolymers at a concentration 
of 5 mg/mL. Z-Ave: Z-Average size (diameter.nm); PDI: Polydispersity index. 
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Concentration 
(mg/mL) 
5 37.5   150  
Z-Ave (d.nm) 163.9 282.9 313.6 
PDI 0.481 0.769 1 
Table 3.5 Dynamic light scattering (DLS) analysis P-Dex-35 kDa-6% at different 
concentration. Z-Ave: Z-Average size (diameter.nm); PDI: Polydispersity index. 
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3.4 Discussion 
 As discussed in the chapter 2, the purpose of this chapter was to define the 
impact of MW and drug loading on PK/BD profile of HPMA copolymer-dexame-
thasone conjugates in a model of localized inflammation.  Thus, we conducted this 
comprehensive comparison in a murine implant loosening model and obtained the 
following finds. 
3.4.1 Impact of Molecular Weight on PK/BD Profile. 
 MW clearly had a major impact on the PK/BD profiles of P-Dex conjugates in 
the gamma counter-based analyses (Figure 3.2).  There was greater uptake and 
retention of the conjugates with the higher MWs in the major organs at every time 
point evaluated, with the kidney as the only exception, which may be due to the 
fact that the HPMA copolymer conjugates are known to be cleared through the 
kidney, and the lower MW conjugates would be expected to have more rapid renal 
clearance [79, 152, 153].  This was also reported in our previous finding when 
analyzing the PK/BD profile of HPMA copolymer conjugates using inflammatory 
arthritis rat model [144].  The %ID/g of most of the P-Dex conjugates in all the 
organs and tissues decreased over time. In this analysis, we also found the 125I 
activity (representing the amount of P-Dex) between the particle-injected left femur 
and nonparticle-injected right femur was not significantly different, which was not 
consistent with our previous findings [154, 155].  The systemic exposure of the 
conjugate increased when the MW was raised. The AUC0-∞ (blood) of the conju-
gates positively correlated with the MW of the conjugates, and Cl of the polymers 
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was negatively correlated to the MW of the polymers.  There is no significant dif-
ference between AUCleft femur/AUCbood and AUCright femur/ AUCbood for all the tested 
polymer conjugates.  Review of the protocol suggests that the discrepancy may be 
attributed to the technical limitation of not being able to isolate the peri-implant 
inflammatory tissue from the surrounding noninvolved tissues. 
 Instead, the whole leg was isolated without perfusion.  Since the tissue samples 
harvested were much larger than the peri-implant inflammatory lesion in this model, 
the radioactivity associated with the large quantities of nonrelevant tissue may 
have masked the small activity of the P-Dex-125I targeted to the peri-implant lesion, 
leading to the inconclusive results.  In order to overcome the limitation of the 
gamma counter-based PK/BD analyses, we conducted a semiquantitative near-
infrared optical imaging-based PK/BD analysis to better recapitulate the passive 
targeting of P-Dex to the peri-implant lesion.  The methodology was successful in 
establishing the preferential localization of the P-Dex in the particle-injected left 
femurs, and this was true for all the polymer conjugates tested.  Furthermore, as 
evident in Figures 3.3 and 3.5, the increase of MW provided longer retention of the 
polymers at the peri-implant inflammatory site and better differentiation of the left 
(with particle infusion) and right (without particle infusion) legs.  Also shown in Fig-
ure 6, there was a trend of increase of ROI signal intensity at 1-day postinjection 
for both P-Dex-35 kDa-12% and P-Dex-45 kDa-12% groups. This may be due to 
recirculation of the copolymers in the system [156]. 
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3.4.2. Impact of Drug Loading on the PK/BD Profile. 
 Based on the findings presented in Figures 3.2 and 3.4 and Table 3.1, higher 
Dex content provided a higher systemic exposure and a longer retention of conju-
gates at the inflammatory site.  An unexpected finding was that the P-Dex with ∼6 
wt % Dex content exhibited unusually rapid elimination in both gamma counter 
analysis and NIR optical imaging studies, which was not found in our previous work 
using inflammatory arthritis rat model [144].  This experiment was repeated multi-
ple times, and the results were confirmed.  Further examination revealed that the 
PBS or DD water solution of P-Dex-30 kDa-6% and P-Dex-35 kDa-6% was cloudy, 
which suggested the potential of polymer aggregation in the solutions.  DLS anal-
yses of the P-Dex-35 kDa-6% in DD water confirmed the presence of aggregates, 
and the aggregation size was positively correlated with the increase of the concen-
tration.  Compared to nonaggregating HPMA copolymers, the P-Dex-35 kDa-6% 
aggregates (>150 nm even after dilution associated with systemic administration) 
may be more rapidly internalized by the mononuclear phagocytic system (MPS), 
leading to their enhanced clearance [157].  The gamma counter-based PK/BD 
analysis, however, did not find high radioactivity in livers or spleens after P-Dex-
35 kDa-6% administration.  The NIR optical imaging (Figure 3.4) seemed to sup-
port a very rapid renal clearance for the polymer.  Clearly, the further investigations 
are necessary to better understand the mechanism of the copolymer aggregation 
and its rapid in vivo clearance.   
 To understand the impact of the P-Dex with different structural parameters on 
cell uptake and sequestration in vitro, BMMs were treated with P-Dex of different 
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MW and Dex content and analyzed at different time points for copolymer uptake 
and sequestration by flow cytometry and fluorescence microscopy.  The results of 
these experiments revealed no significant differences in the kinetics or levels of 
uptake between P-Dex of different MW or Dex content (which correlates with the 
finding of others) [158], suggesting that cell autonomous mechanisms for copoly-
mer uptake and sequestration operate independently of MW or Dex content.  To 
explore cellular uptake in the peri-implant tissue in vivo, Alexa Fluor 488 labeled 
copolymers were given to mice. As shown in Figures 3.6 and 3.7 and Tables 3.2 
and 3.3, the FACS analysis of the peri-implant tissue confirmed that all the copol-
ymers were predominantly taken up by inflammatory myeloid cells (including in-
flammatory monocytes, macrophages, and dendritic cells), with a minor 
component internalized by fibroblastic cells.  For all cell populations analyzed, 
there was a trend toward increased frequencies of cells internalizing copolymer 
with increasing MW. In addition, the increase of Dex content also enhanced the 
cell-mediated sequestration, especially for the CD11c+ cells.  Since our in vitro cell 
culture study suggested that the alteration of MW and Dex content would have 
minimal impact on BMM internalization of the PDex, we speculate that the in-
creased in vivo sequestration of PDex with higher MW polymers and/or higher Dex 
content might be mainly attributed to their increased exposure to the cells as 
demonstrated by their higher t1/2, AUC, MRT, and lower Cl.  The results from this 
comprehensive study are informative in assisting the future structural design of 
HPMA copolymerbased theranostic system for early detection and prophylactic in-
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tervention of peri-implant osteolysis.  Based on the findings of this study, we be-
lieve the use of a high MW (less than 45 kDa to ensure eventual renal clearance) 
HPMA copolymer as the carrier for MRI, SPECT/CT, or PET/CT imaging modali-
ties may provide the best early diagnostic tool.  While this high MW would also 
cause the imaging probe’s distribution to off-target anatomical locations, its poten-
tial risk of off-target toxicity is minimal due to its infrequent use and relatively low 
dosing level.  For therapeutic intervention, the data from the current study also 
suggest that the use of a high MW (but less than 45 kDa to ensure eventual renal 
clearance) HPMA copolymer as the drug carrier to ensure the optimal targeting to 
the periimplant inflammatory lesion.  The off-target distribution and associated tox-
icities, however, cannot be underestimated in this case.  While our previous study 
suggests the long-term use of P-Dex in managing peri-implant osteolysis may not 
cause systemic osteopenia [119], its impact on other sensitive organs and tissues 
(e.g., adrenal gland) is yet to be evaluated.  If the safety profile of the HPMA co-
polymer−drug conjugate is not acceptable, a localized delivery strategy may be 
considered as an alternative. Though the mechanism is not yet understood, the 
finding of P-Dex aggregation at certain Dex content (6 wt %) must be carefully 
evaluated when considering clinical translation of this potential macromolecular 
prodrug conjugate, in order to ensure safety and a favorable PK/BD profile.  
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3.5 Conclusion  
 Using gamma counter-based and optical imaging-based methodologies, we 
evaluated the impact of structural parameters (i.e., molecular weight and drug con-
tent) on the pharmacokinetic and biodistribution (PK/BD) profiles of HPMA copol-
ymer-dexamethasone conjugates in an aseptic peri-implant 
inflammation/osteolysis mouse model.  The study found that the increase of both 
the MW and Dex content facilitated targeting of P-Dex to sites of local inflammation 
through increasing systemic exposure and reduced renal clearance of the conju-
gates.  At certain level of Dex content (6 wt %), P-Dex may aggregate, leading to 
a more rapid elimination of the copolymers from the system.  Our findings will as-
sist in the future design and development of HPMA copolymer-based theranostic 
platform for early detection and therapeutic intervention of peri-implant osteolysis 
and implant failure. 
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CHAPTER 4  
IN VIVO EVALUATION OF MACROMOLECULAR PRODRUG WITH DRUG-
CONTAINING MONOMERS THERAPEUTIC EFFICACY AND REDUCTION OF 
TOXICITY 
4.1 Introduction 
 As discussed in Chapter 1, drug releasing kinetic would have influence on the 
drug therapeutic efficacy and toxicity reduction.   
4.2 Materials and Methods  
4.2.1 Instruments 
 Isoflurane vaporizer (Midmark Corp, Dayton, OH) was used to anesthetize an-
imals during arthritis induction.  Rats ankle diameter were measured using a digital 
caliper (World Prescision Instruments, Inc., Saraspta, FL, USA).  Bone quality were 
analyzed using a Skyscan 1172 high resolution micro-CT system (Skyscan, Kon-
tich, Belgium).  A Faxitron® MX-20 Cabinet X-ray System (Tucson, Arizona, USA) 
was used to monitor the hard tissue decalcification progress.  A Leica RM2255 
rotary microtome (Leica Biosystems Inc., Buffalo Grove, IL, USA) was used for 
paraffin-embedded tissue sectioning. 
4.2.2 The therapeutic evaluation of HPMA copolymers conjugates in adjuvant-in-
duced arthritis rats 
 Male Lewis rats (175-200 g) obtained from Charles River Laboratories (Wil-
mington, MA, USA) were used to establish the adjuvant-induced arthritis (AA) rat 
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model as described previously [146].  The rats were randomly divided into seven 
groups: P-Dex-A, P-Dex-C, P-Dex-D, and P-Dex-E treatment (n = 7, single i.v. 
injection on day 14 post-induction, dose equivalent of Dex = 10 mg/kg), Dexame-
thasone Sodium Phosphate treatment (n=7, equivalent of Dex = 10 mg/kg, divided 
into 4 aliquots and injected on Day 14, 15, 16, 17), and saline control (n=4).  An 
additional group (n=4) of healthy rats were used as a negative control.  Rats’ joint 
edema and body weight were monitored daily from day 11.  Blood was collected 
for liver enzyme analysis at necropsy.  All major organs and limbs were collected 
at the euthanasia and fixed with buffered formalin before paraffin embedding at 
day 44.   All animal experiments were performed in accordance with protocols ap-
proved by the Institutional Animal Care and Use Committee (IACUC) of the Uni-
versity of Ne-braska Medical Center or Hospital for Special Surgery. 
4.2.3 Observational assessment of AA rats’ joint inflammation  
 The articular index (AI) score was recorded during the treatment by the same 
observers (XW and GZ) as described previously.  An AI score was given to each 
hind limb from day 11 to day 56 post-arthritis induction.  The AI scoring system is 
based on a 0-4 numeric system as the following: 0 = no signs of swell-ing or ery-
thema; 1 = slight swelling and/or erythema; 2 = low-to-moderate edema and signs 
involving the tarsals; 3 = pronounced edema with limited use of the joint and signs 
extending to the metatarsals; 4 = excessive edema with joint ri-gidity and severe 
signs involving the entire hind paw.  The sum of the two hind limb scores for each 
animal was recorded.  Ankle diameter (medial to lateral) was measured using a 
digital caliper as confirmation of inflammation-associated edema/hyperplasia. 
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4.2.4 Micro-CT analysis of articular bone quality 
 Hind limbs were isolated after euthanasia and fixed with buffered formalin for 
no less than 48 hr.  The ankle joint bone quality was analyzed using a Skyscan 
1172 micro-CT system.  Micro-CT scanning parameters were set as fol-lows: volt-
age, 70 kV; current, 142 μA; exposure time, 1915 ms; resolution, 13.26 μm; with 
aluminum filter (0.5 mm); rotation step = 0.4°; frame averaging = 4; random move-
ment = 10; using 180° rotation scanning.  Raw data were reconstructed using 
NRecon to obtain a visual representation of the results, and the volume rendering 
of the samples were performed via CTvox software (Skyscan).  To quantitatively 
compare the four treatments, the entire calcaneus and the selected region of in-
terest (ROI) of the trabecular bone within the calcaneus were used as the anatom-
ical sites for micro-CT analyses.  The ROI was defined by aligning the calcaneus 
bone along the sagittal plane using Data-viewer, with the ROI starts at the 75th 
slide away from the epiphyseal plate and continues for 76 slides (1.98 mm).  The 
diameter of the cylindrical ROI was set at 1.00 mm.  The morphometric parameters, 
such as percent bone volume (BV/TV), bone surface density (BS/TV), trabecular 
separation (Tb.Sp), trabecular number (Tb.N), bone mineral density (BMD), and 
trabecular thickness (Tb.Th) were cal-culated using CTAn (Skyscan 
4.2.5 Statistical methods 
 Two-way analysis of variance (ANOVA), followed by Tukey’s post hoc test to 
account for multiple comparisons, was used for data analysis using GraphPad 
Prism Software.  P-values ≤ 0.05 were considered statistically significant. 
91 
 
4.3 Results 
4.3.1 The polymers provides different pattern of sustained amelioration of joint in-
flammation in AA rats 
 Ankle diameter and AI score of the P-Dex-A, P-Dex-C, P-Dex-D, P-Dex-E, and 
Dex treated group exhibited different outcome upon treatment.  Dex treated group 
showed an immediate recovery of the swelling, however, a dramatic flare upon 
cessation of Dex treatment on day 19 (Figure 4.1).  A single injection of Dex con-
taining HPMA conjugates (dose equivalent to the Dex treatment) resulted in differ-
ent level of reductions in ankle swelling and AI score from day 15 to 44.  The ankle 
diameter difference significance of different treatment group was summarized in 
Table 4.1, Table 4.2 and Table 4.3 for the comprehensive comparison.  The ther-
apeutic efficacy difference was also in agreement of the in vitro releasing profiles 
of the polymer conjugates (Figure 2.8).    
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Figure 4.1 HPMA conjugates polymerized with different dexamethasone con-
taining monomers showed different therapeutic effect on amelioration of joint in-
flammation in an adjuvant-induced arthritis (AA) rat model.  (A) The change of AA 
rats’ left ankle joint size of different groups during the treatment study; (B) The 
change of articular index score of different groups during the treatment study.  The 
red arrow indicated the day when rats received the single conjugates injection and 
the daily free Dex treatment was initiated.  The green arrow indicated the day when 
rats received their last free Dex treatment.  The prevention of arthritic ankle swell-
ing by single injection of P-Dex-E was sustained for about one month from day 15 
to day 44.   
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 Day 
0 
Day 
11 
Day 
12 
Day 
13 
Day 
14 
Day 
15 
Day 
16 
Day 
17 
Day 
18 
Day 
19 
Day 
20 
Day 
21 
P-Dex-A 
vs.  
P-Dex-C 
ns ns ns ns ns **** **** **** **** **** **** **** 
P-Dex-A 
vs.  
P-Dex-D 
ns ns ns ns ns ns ns ns ns ns * ns 
P-Dex-A 
vs.  
P-Dex-E 
ns ns ns ns ns ns ns ns ** *** ** ** 
P-Dex-A 
vs.  
Dex 
ns ns ns ns ns **** **** **** **** **** ** ns 
P-Dex-A 
vs.  
Saline  
ns ns ns ns ns ns * ** *** ** ** ** 
P-Dex-A 
vs. 
Healthy 
ns **** **** **** **** **** **** **** **** **** **** **** 
P-Dex-C 
vs.  
P-Dex-D 
ns ns ns ns ns *** **** **** **** **** **** **** 
P-Dex-C 
vs. 
P-Dex-E 
ns ns ns ns ns *** **** **** * ** ns ns 
P-Dex-C 
vs. 
Dex 
ns ns ns ns ns ns * ** ** ns ns *** 
P-Dex-C 
vs.  
Saline  
ns ns ns ns ns **** **** **** **** **** **** **** 
P-Dex-C 
vs. 
Healthy 
ns ** **** **** **** **** **** **** **** **** **** **** 
P-Dex-D 
vs.  
P-Dex-E 
ns ns ns ns ns ns ns ** **** **** **** **** 
P-Dex-D 
vs.  
Dex 
ns ns ns ns ns **** **** **** **** **** **** ** 
P-Dex-D 
vs.  
Saline  
ns ns ns ns ns * ns ns ns ns ns ns 
P-Dex-D 
vs. 
Healthy 
ns **** **** **** **** **** **** **** **** **** **** **** 
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P-Dex-E 
vs.  
Dex 
ns ns ns ns ns **** **** **** **** ** ns ns 
P-Dex-E 
vs.  
Saline  
ns ns ns ns ns * **** **** **** **** **** **** 
P-Dex-E 
vs. 
Healthy 
ns **** **** **** **** **** **** **** **** **** **** **** 
Dex  
vs.  
Saline  
ns ns ns ns ns **** **** **** **** **** **** **** 
Dex  
vs. 
Healthy 
ns **** **** **** **** **** **** **** **** **** **** **** 
Saline  
vs. 
Healthy 
ns **** **** **** **** **** **** **** **** **** **** **** 
Table 4.1 The statistical analyses of the joint diameter of the rats from different 
treatment groups from Day 11 to Day 21 including the day of the adjuvant induction 
Day 0.  Two-way analysis of variance (ANOVA), followed by Tukey’s post hoc test 
to ac-count for multiple comparisons, was used for data analysis using GraphPad 
Prism Software.  (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001). 
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 Day 
22 
Day 
23 
Day 
24 
Day 
25 
Day 
26 
Day 
27 
Day 
28 
Day 
29 
Day 
30 
Day 
31 
Day 
32 
Day 
33 
P-Dex-A 
vs.  
P-Dex-C 
**** ** ns ns ns ns ns ns ns ns ns ns 
P-Dex-A 
vs.  
P-Dex-D 
ns ns ns ns ns ns ns * ns ns ns ns 
P-Dex-A 
vs.  
P-Dex-E 
** * ** * * ** ** ** * * ** ** 
P-Dex-A 
vs.  
Dex 
ns ns ns ** ** ** ** ** ** ** * * 
P-Dex-A 
vs.  
Saline  
** ** * ** * * ** ** ** ** * * 
P-Dex-A 
vs. 
Healthy 
**** **** **** **** **** **** **** **** **** **** **** **** 
P-Dex-C 
vs.  
P-Dex-D 
**** **** **** **** *** **** *** *** ** * * ns 
P-Dex-C 
vs.  
P-Dex-E 
ns ns ns ns ns ns ns ns ns ns ns ns 
P-Dex-C 
vs. 
 Dex 
**** **** **** **** **** **** **** **** **** *** ** ** 
P-Dex-C 
vs.  
Saline  
**** **** **** **** **** **** **** **** **** *** ** ** 
P-Dex-C 
vs. 
Healthy 
**** **** **** **** **** **** **** **** **** **** **** **** 
P-Dex-D 
vs.  
P-Dex-E 
**** **** **** **** **** **** **** **** **** **** **** **** 
P-Dex-D 
vs.  
Dex 
ns ns ns ns ns ns ns ns ns ns ns ns 
P-Dex-D 
vs.  
Saline  
ns ns ns ns ns ns ns ns ns ns ns ns 
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P-Dex-D 
vs. 
Healthy 
**** **** **** **** **** **** **** **** **** **** **** **** 
P-Dex-E 
vs.  
Dex 
** *** **** **** **** **** **** **** **** **** **** **** 
P-Dex-E 
vs.  
Saline  
**** **** **** **** **** **** **** **** **** **** **** **** 
P-Dex-E 
vs. 
Healthy 
**** **** **** **** **** **** **** **** **** **** **** **** 
Dex  
vs. Sa-
line  
* ns ns ns ns ns ns ns ns ns ns ns 
Dex  
vs. 
Healthy 
**** **** **** **** **** **** **** **** **** **** **** **** 
Saline  
vs. 
Healthy 
**** **** **** **** **** **** **** **** **** **** **** **** 
Table 4.2 The statistical analyses of the joint diameter of the rats from different 
treatment groups from Day 22 to Day 33 including the day of the adjuvant induction 
Day 0.  Two-way analysis of variance (ANOVA), followed by Tukey’s post hoc test 
to ac-count for multiple comparisons, was used for data analysis using GraphPad 
Prism Software.  (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001). 
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 Day 
34 
Day 
35 
Day 
36 
Day 
37 
Day 
38 
Day 
39 
Day 
40 
Day 
41 
Day 
42 
Day 
43 
Day 
44 
P-Dex-A 
vs.  
P-Dex-C 
ns ns ns ns ns ns ns ns ns ns ns 
P-Dex-A 
vs.  
P-Dex-D 
ns ns ns ns ns ns ns ns ns ns ns 
P-Dex-A 
vs.  
P-Dex-E 
** ** ns ns ns ns ns ns ns ns ns 
P-Dex-A 
vs.  
Dex 
* * ** * ns ns ns ns ns ns ns 
P-Dex-A 
vs.  
Saline  
ns * ** * * * ns ns ns * ns 
P-Dex-A 
vs. 
Healthy 
**** **** **** **** **** **** **** **** **** **** **** 
P-Dex-C 
vs.  
P-Dex-D 
ns ns ns ns ns ns ns ns ns ns ns 
P-Dex-C 
vs.  
P-Dex-E 
ns ns ns ns ns ns ns ns ns ns ns 
P-Dex-C 
vs.  
Dex 
** ** * * ns ns ns ns ns ns ns 
P-Dex-C 
vs.  
Saline  
* ** * * * * ns ns ns * ns 
P-Dex-C 
vs. 
Healthy 
**** **** **** **** **** **** **** **** **** **** **** 
P-Dex-D 
vs.  
P-Dex-E 
**** **** *** ** ** *** ** ** ** * ns 
P-Dex-D 
vs.  
Dex 
ns ns ns ns ns ns ns ns ns ns ns 
P-Dex-D 
vs.  
Saline  
ns ns ns ns ns ns ns ns ns ns ns 
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P-Dex-D 
vs. 
Healthy 
**** **** **** **** **** **** **** **** **** **** **** 
P-Dex-E 
vs.  
Dex 
**** **** **** **** *** *** ** ** ** ** ns 
P-Dex-E 
vs.  
Saline  
**** **** **** **** **** **** *** *** *** **** ** 
P-Dex-E 
vs. 
Healthy 
**** **** **** **** **** **** **** **** **** **** **** 
Dex  
vs. Sa-
line  
ns ns ns ns ns ns ns ns ns ns ns 
Dex  
vs. 
Healthy 
**** **** **** **** **** **** **** **** **** **** **** 
Saline  
vs. 
Healthy 
**** **** **** **** **** **** **** **** **** **** **** 
Table 4.3 The statistical analyses of the joint diameter of the rats from different 
treatment groups from Day 34 to Day 44 including the day of the adjuvant induction 
Day 0.  Two-way analysis of variance (ANOVA), followed by Tukey’s post hoc test 
to ac-count for multiple comparisons, was used for data analysis using GraphPad 
Prism Software.  (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001). 
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4.3.2 The polymers provides different protection of joint bone structure in AA rats 
 The most severe bone damage was found in the saline group, with extensive 
erosion of the entire distal tibia.  P-Dex-A, P-Dex-C, P-Dex-D, and P-Dex-E treated 
animals demonstrated different level of reduced ankle bone erosion compared to 
the saline group.  One month following the single dose polymer administration, 
there were only minor bone erosion found in P-Dex-A, P-Dex-C and P-Dex-E 
treated groups.  The quantitative analysis of the hind paw calcaneus trabecular 
bone (Figure 4.2 A) micro-CT data showed that P-Dex-A, P-Dex-C and P-Dex-E 
treatment preserved the bone quality at different level (different P value compared 
with Saline control group), as is evident in the morphometric parameters, such as 
percent BV/TV, BS/TV, Tb.Sp, Tb.N, BMD, and Tb.Th, with their values similar to 
those observed for healthy controls, and significantly better than those observed 
for the free Dex-treated. When the entire calcaneus bone was analyzed (Figure 
4.2 B), the P-Dex-D, Dex and saline groups were found with significantly increased 
calcaneus tissue volume, calcaneus total porosity and calcaneus bone surface and 
significantly decreased calcaneus bone volume percentage, when compared to 
the healthy and P-Dex-A, P-Dex-C and P-Dex-E treated groups. 
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Figure 4.2 Micro-CT analyses of the hind paw of the rats from different treatment 
groups. (B) Bone morphometric parameters of the trabecular bone ROI within cal-
caneus bone. (C) Bone morphometric parameters of the entire calcaneus bone. (*, 
P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001). 
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4.4 Discussion  
 The HPMA polymer conjugates polymerized with different Dex-containing mon-
omers synthesized in Chapter 2 were validated the difference therapeutic efficacy 
in this chapter.  The adjuvant induced arthritis rats model were used for the proof-
of-concept.  The amelioration of the rats’ ankles swelling which was measured 
daily showed different trend in the rats received different treatment on day 14 post-
induction.  It was found that the drug releasing rates may have significant impact 
on the drug therapeutic effect.  For example, the significant joint amelioration of 
the P-Dex-C and P-Dex-E treatment was found from the following day post-injec-
tion on Day 15 compared with Saline treated group.  This significance between P-
Dex-E and Saline was found until the animals were sacrificed.  However, the sig-
nificance between P-Dex-C and Saline groups showed smaller from Day 31 (from 
P value <0.0001 to a higher P value), until Day 40 (26 days after injection) when 
significance can hardly be found in joints diameter data.  This phenomena corre-
lated with the fast Dex releasing profile of P-Dex-C than P-Dex-E, which can offer 
an immediate therapeutic effect but shorter sustention.  This shorter sustention 
may also lead to a less protection of the bone structure than P-Dex-E showed in 
those Micro-CT data, such like trabecular bone percentage (Figure 4.2).  When 
comparing P-Dex-A and P-Dex-E therapeutic efficacy using Saline as a control 
group, we could learn that the P-Dex-A treated animals started to show significant 
reduced joints diameter from Day 16 (the third day after injection), which is slower 
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than P-Dex-E, correlated with the Dex in vitro releasing profile that P-Dex-A re-
leased slower than P-Dex-E cannot offer as the same immediate anti-inflammatory 
effect as P-Dex-E.  The joints diameter reduction significance of of P-Dex-A treat-
ment compared with Saline treatment showed smaller than that P-Dex-C and P-
Dex-E compared with Saline (bigger or equal P value in the comparison between 
P-Dex-A and Saline than it was between P-Dex-C and Saline or between P-Dex-
E and Saline at the same day).  In The fast releasing polymer (P-Dex-C) would 
show the faster therapeutic action (Figure 4.1), however, would also show an ob-
vious disease activity flare which may because the active ingredient (Dex) in the 
macromolecular conjugates were less than its therapeutic concentration threshold.  
Insufficient dosage may not only cause the disease flare in the fast releasing drug 
treatment after a burst release, but also may cause the unobvious therapeutic out-
come in the slow releasing treatment (P-Dex-D, which showed the slowest releas-
ing rate in the pH 7.4).  With the even slower releasing rate in the lysosomal acidic 
condition (pH 5.0), P-Dex-D showed a slight better improvement of the ankle joint 
protection than Saline treatment (joints’ diameter significant smaller than those of 
Saline treated group on only Day 15, no significant bone structure protection was 
found in micro-CT analyses compared with Saline group).  This may be the con-
sequence of that slow-releasing may not offer enough therapeutic active ingredient 
at the inflammatory site.  However, to different degree, the P-Dex-A and P-Dex-E 
showed a sustained protection for the rats’ ankle.  When approaching to the end 
of this animal study, the ankles from the rats received P-Dex-E showed a trend to 
start swelling, while the diameter of the ankles from the rats received P-Dex-A was 
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still decreasing although it was not significant compared with Saline treatment 
group because this animal model can self-recover.  Considering in both pH7.4 and 
pH 5.0, P-Dex-A showed slower releasing rates than P-Dex-E, the results from the 
in vivo assessment was in agreement of the in vitro releasing study.  P-Dex-E may 
show a better therapeutic efficacy when comparing the treatment of P-Dex-A and 
P-Dex-E at the same day post-treatment, at the same dosing level.  However, to 
further conclude if P-Dex-E or P-Dex-A was the better therapeutic would need 
more evaluation on their effects on reduction the Dex side effect which may be 
done in the future and a fully dose escalation comparison study.  
4.5 Conclusion  
 We proved the therapeutic efficacy was highly related to the macromolecular 
conjugates’ releasing kinetics.  We also provided the chemical structure guidance 
for the future drug designation for different releasing rate purpose of use.   
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CHAPTER 5 
DESIGN, SYNTHESIS AND CHARACTERIZATION OF MACROMOLECULAR 
PRODRUG OF TOFACITINIB 
5.1 Introduction 
 As an emerging class of medication, Janus kinase (JAK) inhibitors offer an al-
ternative for RA patients who have experienced severe side effects or are refrac-
tory to current treatments.  Tofacitinib (Tofa, CP-690 550), is a JAK inhibitor that 
exhibits functional selectivity for JAK1/3 and JAK1/2 signaling pathways.  It was 
approved by the US Food and Drug Administration in 2012 for the treatment of 
adults with moderate-to-severe RA who have had an inadequate response or who 
are intolerant to methotrexate (MTX).  Recent results from randomized clinical tri-
als indicate that Tofa, used either as monotherapy [159-163] or in combination 
[164-167] with MTX or other non-biologic disease-modifying anti-rheumatic drugs 
(DMARDs) [168], leads to clinical improvement compared to placebo or MTX alone 
in patients with moderate-to-severe RA. 
 As a potent suppressor of innate and adaptive immunity, Tofa has been asso-
ciated with dose-dependent toxicity, including higher risk of infections, malignancy, 
liver toxicity and hematologic abnormalities, which at least in part can be attributed 
to its the ubiquitous biodistribution [169].  We hypothesized that the development 
of a macromolecular prodrug of Tofa would modify its pharmacokinetics and bio-
distribution (PK/BD) pattern, favoring deposition in arthritic joints, which in turn 
could widen the drug’s therapeutic window with sustained efficacy, providing the 
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opportunity for future development of safer Tofa dosing regimens.  To test this 
hypothesis, a Tofa prodrug (P-Tofa) was synthesized by conjugating Tofa to a wa-
ter-soluble, biocompatible N-(2-hydroxypropyl) methacrylamide (HPMA) copoly-
mer via a hydrolysable carbamate linker (Figure 5.1).   
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Figure 5.1 A macromolecular prodrug of Tofacitinib (P-Tofa).  (A) The synthesis of 
HEMA-Tofa monomer; (B) The synthesis of P-Tofa. 
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5.2 Materials and Methods  
5.2.1 Materials 
 N-(2-Hydroxypropyl) methacrylamide (HPMA), S,S′-bis(α,α′-dimethyl-α″-acetic 
acid)-trithiocarbonate, and N,N-dioctadecyl-N",N"-bis(2-hydroxyethyl)-1,3-pro-
panediamine (LA) were prepared as described in chapter 2.  Tofacitinib and Tofa-
citinib citrate were purchased from JINLAN Pharm-Drugs Technology Co., Ltd 
(Hangzhou, China).  IRDye® 800CW carboxylate was purchased from LI-COR, 
Inc. (Lincoln, NE, USA).  Alexa Fluor® 647 NHS ester was purchased from Life 
Technologies, Inc. (Eugene, OR, USA).  All other reagents and solvents, if not 
specified, were purchased from either Sigma-Aldrich (St. Louis, MO, USA) or 
Acros Organics (Morris Plains, NJ, USA).  All compounds were reagent grade and 
used without further purification. 
5.2.2 Instruments 
 1H and 13C NMR spectra were recorded on a 500 MHz NMR spectrometer (Var-
ian, Palo Alto, CA, USA).  The weight average molecular weight (Mw) and number 
average molecular weight (Mn) of copolymers were determined by size exclusion 
chromatography (SEC) using an ÄKTA FPLC system (GE HealthCare, Chicago, 
IL) equipped with UV and RI (KNAUER, Berlin, Germany) detectors.  SEC meas-
urements were performed on a Superdex 200 column (HR 10/30) with phosphate-
buffered saline (PBS, pH=7.4) as the eluent.  HPMA homopolymer (PHPMA) sam-
ples with narrow polydispersity were used as calibration standards.  HPLC anal-
yses were performed on an Agilent 1100 HPLC system (Agilent Technologies, Inc., 
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Santa Clara, CA) with a Hypersil™ ODS C18 Columns (Thermo Scientific, Wal-
tham, MA). 
5.2.3 Synthesis of methacryloxyethyl chloroformate (HEMA-COCl) 
 Triphosgene (1710 mg, 5.7 mmol) in dichloromethane (4 mL, anhydrous) was 
added dropwise into a solution of hydroxyethyl methacrylate (HEMA, 500 mg, 3.8 
mmol) and triethylamine (390 mg, 3.8 mmol) in dichloromethane (6 mL, anhydrous) 
maintained in an ice bath.  The resulting mixture was stirred in the ice bath for 1 hr 
and then at room temperature for 1 hr.  After removal of the solvent and excess 
phosgene using a rotary evaporator, the resultant white residue was extracted with 
dry ether (5 mL).  The solid was filtered and the filtrate was concentrated to give 
HEMA chloroformate as colorless oil (715 mg, 96% yield). 
1H NMR (500 MHz, CDCl3): δ = 6.16 (m, 1H, =CH2), 5.64 (m, 1H, =CH2), 4.56 
(t, J = 4.5 Hz, 2H, -CH2-), 4.42 (t, J = 4.5 Hz, 2H, -CH2-), 1.96 (s, 3H, -CH3); 13C 
NMR (125.7 MHz, CDCl3): δ = 166.89 (O-C=O), 150.86 (Cl-C=O), 135.59 (=C), 
126.62 (=CH2), 69.02 (-CH2-), 61.51 (-CH2-), 18.21 (-CH3).  
5.2.4 Synthesis of Tofa-containing monomer (HEMA-Tofa) 
 HEMA-COCl (370 mg, 1.92 mmol) in dichloromethane (5 mL, anhydrous) was 
added dropwise into a solution of Tofa (500 mg, 1.60 mmol) and diisopropylethyl-
amine (DIPEA, 310 mg, 2.40 mmol) in dichloromethane (15 mL, anhydrous) main-
tained in an ice bath.  The reaction mixture was stirred in the ice bath for 1 hr before 
quenching with water (10 mL).  The organic layer was separated and washed with 
brine, then dried over anhydrous magnesium sulfate.  After removal of the solvent, 
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the resulting light-yellow residue was subjected to flash column chromatography 
(CH2Cl2:CH3OH = 20:1) to afford the monomer as a white solid (715 mg, 95% yield). 
1H NMR (500 MHz, CDCl3): δ = 8.44 and 8.42 (s, 1H), 7.41 and 7.40 (d, J = 4.2 
Hz, 1H), 6.64 and 6.58 (d, J = 4.2 Hz, 1H), 6.16 (s, 1H), 5.60 (s, 1H), 5.08 (br, 1H), 
4.71 (t, J = 3.6 Hz, 2H), 4.54 (t, J = 3.6 Hz, 2H), 4.05 (dd, J1 = 13.2, J2 = 4.2 Hz, 
0.5H), 4.07-3.45 (m, 6.5H), 3.33 (s, 3H), 2.51 and 2.46 (p, J = 6.1, 1H), 1.94 and 
1.96 (s, 3H), 1.89-1.85 (m, 1H), 1.76-1.66 (m, 1H), 1.09 and 1.06 (d, J = 7.1 Hz, 
3H);  13C NMR (125.7 MHz, CDCl3): δ = 167.05 (O-C=O), 160.82, 160.38, 157.61, 
157.52, 153.04, 153.01, 148.87 (N-C=O), 135.78, 126.36, 126.24, 121.60, 121.44, 
114.33, 114.12, 106.21, 105.99, 105.17, 65.16, 65.06, 62.20, 61.98, 53.86, 53.58, 
46.71, 43.74, 42.76, 39.48, 35.21, 34.75, 31.48, 31.22, 29.66,  25.20, 25.15, 18.25, 
18.29 (CH3), 14.25, 14.10.  ESI-MS: [M+H]+ = 468.8. 
5.2.5 Synthesis of HPMA copolymer-Tofa conjugate (P-Tofa) via RAFT copolymer-
ization 
 HPMA (3712 mg, 22.47 mmol) and HEMA-Tofa (750 mg, 1.60 mmol) were dis-
solved in anhydrous dimethyl sulfoxide (DMSO, 21 mL) with 2,2′-azobisisobu-
tyronitrile (AIBN, 37.7 mg, 0.17 mmol) as initiator and S,S′-bis(α, α′-dimethyl-α″-
acetic acid)-trithiocarbonate (CTA, 33.7mg, 0.13 mmol) as the RAFT agent.  The 
solution was purged with argon and polymerized at 60 °C for 40 hr.  The resulting 
polymer was first purified by precipitation in acetone/diethyl ether (v/v = 1:1, 200 
mL) twice to remove the unreacted low molecular weight compounds, and then 
dialyzed against ddH2O.  The molecular weight cutoff size of the dialysis tubing 
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was 25 kDa of globular protein.  The resulting solution was then lyophilized to af-
ford the final P-Tofa (4.21 g).   
 To quantify Tofa loading, P-Tofa (1 mg/mL) was hydrolyzed in 0.01 N NaOH in 
CH3OH overnight.  The resulting solution was neutralized and analyzed with HPLC 
(mobile phase: acetonitrile/water = 3/1; detection, UV 284 nm; flow rate = 1 mL/min; 
injection volume = 20 μL).  The analyses were performed in triplicate.  The mean 
value and standard deviation were obtained with Microsoft Excel. 
5.2.6 The synthesis of P-Tofa-APMA 
 To introduce fluorescent labels to the P-Tofa for biodistribution and immunoflu-
orescence analysis, primary amine was introduced into P-Tofa using the following 
procedure: HPMA (700 mg, 4.89 mmol) and HEMA-Tofa (142 mg, 0.3 mmol) were 
dissolved in anhydrous dimethyl sulfoxide (DMSO, 6 mL), N-(3-aminopropyl) meth-
acrylamide hydrochloride (APMA, 9.5 mg, 0.05 mmol), 2,2′-azobisisobutyronitrile 
(AIBN, 7.11 mg, 0.04 mmol) as initiator and S,S′-bis(α, α′-dimethyl-α″-acetic acid)-
trithiocarbonate (CTA, 6.79mg, 0.02 mmol) as the RAFT agent, placed in an am-
pule, and purged with argon and polymerized at 60 °C for 40 hr.  The resulting 
polymer was first purified by precipitation in acetone/diethyl ether (v/v = 1:1, 200 
mL) twice to remove the unreacted low molecular weight compounds, and then 
dialyzed against ddH2O.  The amine content of the copolymer was determined as 
3.56×10-5 mol/g using the ninhydrin assay. 
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5.2.7 The synthesis of P-Tofa-IRDye 
 To monitor its distribution after systemic administration, P-Tofa was labeled 
with IRDye® 800CW.  The labeling procedure is briefly described as follows: 
IRDye® 800CW carboxylate (1.25 mg, 1.1 µmol), N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDC, 1.56 mg, 8.1 mmol) and hydroxybenzotria-
zole (HOBt, 0.49 mg, 3.6 mmol) were dissolved in N,N-dimethylformamide (DMF, 
1 mL) in dark at 21 C and stirred for 30 min.  DIPEA (7 mg, 0.054 mmol) and P-
Tofa-APMA (50 mg, [NH2] = 1.78 µmol) in DMF (1 mL) were added into the reaction 
mixture and then stirred overnight.  The reaction solution was dialyzed to remove 
DMF and low molecular weight reactants.  P-Tofa-IRDye was then obtained via 
lyophilization with [IRDye® 800CW] = 6.88 ×10-6 mol/g of the conjugate. 
5.2.8 The synthesis of P-Tofa-Alexa 
 To monitor the cellular sequestration of the P-Tofa in the rat after systemic ad-
ministration, P-Tofa was labeled with Alexa Fluor® 647.  The labeling procedure is 
briefly described as follows: Alexa Fluor™ 647 NHS Ester (1 mg, 0.8 µmol), DIPEA 
(3.5 mg, 0.027 mmol) and P-Tofa-APMA (50 mg, [NH2] = 1.78 µmol) were dis-
solved in N,N-dimethylformamide (DMF, 1 mL) in dark at 21 C and stirred over-
night.  The reaction solution was dialyzed to remove DMF and low molecular 
weight reactants.  P-Tofa-IRDye was then obtained via lyophilization with [50] = 
5.62×10-6 mmol/g of the conjugate. 
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5.2.9 In vitro Tofa release from P-Tofa 
 P-Tofa conjugates (~ 3 mg) were dissolved in 5 mL of buffer solutions with 0.2% 
sodium dodecyl sulfate (SDS, to create the “sink” condition) and different pH val-
ues (pH=7.4, pH=5.5, pH =10), and rats’ serum (Invitrogen).  The release experi-
ments were conducted in a shaking water bath (37 °C, shaking rate 20 rpm).  
Hydrolysis samples (400 µL) were withdrawn at designated time points.  The re-
leased Tofa was extracted with ethyl acetate (1200 µL), with a recovery rate at 
94.3±0.48%.  The solution of Tofa (300 µL) was subsequently dried using a cen-
trifugal evaporator.  The sample was then stored at -80 °C for HPLC analysis as 
described above.  
5.3 Results  
5.3.1 Characterization of P-Tofa 
 P-Tofa has a weight average molecular weight (Mw) of 30.4 kDa, a number 
average molecular weight (Mn) of 23 kDa and a polydispersity index (PDI) of 1.32, 
representing a narrow polydispersity.  The Tofa drug loading in P-Tofa was found 
to be ~ 13 wt%.  The in vitro Tofa release rate was found to be highly dependent 
upon buffer pH values (Figure 5.2).  Both acidic and basic pH environments accel-
erated Tofa release, when compared to the release rate at pH 7.4.  The presence 
of serum proteins in the releasing medium was also found to increase the Tofa 
release rate.  Under each condition tested, intact Tofa was gradually released from 
P-Tofa.  Interestingly, Tofa degradation was observed over time in the basic buffer 
(pH 10), which is in agreement with previous findings [170].  During the course of 
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the experiment (20 days), the release rates of Tofa from P-Tofa at pH = 5.5 and 
7.4, in the rat serum averaged at ~1.5%, 2% and 2.5% of the loaded drug per day, 
respectively. 
 
Figure 5.2 In vitro Tofa release from P-Tofa at pH = 5.0, 7.4, 10.0 and in rat serum.  
The mean values and standard deviation were calculated with GraphPad Prism, n 
= 3. 
5.4 Discussion  
 In recent years, significant progress has been made in understanding the es-
sential role of specific proinflammatory cytokines and other immunological pro-
cesses responsible for RA initiation and progression [17, 171].  Subsequent 
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studies showed that the receptors for several proinflammatory cytokines exert their 
effects through the activation of intracellular signaling pathways mediated by a 
unique family of Janus kinases that phosphorylate downstream molecular targets 
that control key inflammatory and immunological processes [172, 173].  This led 
to the development of Tofacitinib (Tofa, CP-690 550), the first selective JAK inhib-
itor tested in humans.  Tofa inhibits both JAK3 and JAK1, to a lesser extent JAK2, 
and was found to be effective in disease suppression in a variety of clinical condi-
tions and experimental models ranging from inflammatory arthritis, autoimmune 
disorders and transplantation.  A major challenge in the development of JAK inhib-
itors for the treatment of inflammatory and autoimmune disorders has been their 
ubiquitous expression in multiple tissues and cell types, and the broad range of 
biological activities that they control.  Thus, despite demonstrated efficacy in RA, 
their systemic administration is associated with many serious and potentially life 
threatening adverse side effects, including infections, malignancy, liver toxicity and 
hematologic abnormalities [169].  We hypothesized that selective targeting of Tofa 
to sites of joint inflammation might substantially enlarge the therapeutic window of 
Tofa, with the potential for an improved safety profile.  We have previously shown 
in animal models that the macromolecularization of glucocorticoids significantly 
potentiates their therapeutic efficacy and reduces systemic toxicities [146, 147, 
174, 175], via a unique targeting pattern of macromolecular prodrugs based on the 
ELVIS mechanism (Extravasation through Leaky Vasculature and Inflammatory 
cell-mediated Sequestration), in which the systemically administered prodrug ex-
117 
 
travasates through the leaky vasculature at the inflammatory lesion and is seques-
tered locally via inflammatory cell infiltrates and activated resident cells [134].  Con-
currently, for systemic inflammatory conditions, a fraction of the nanomedicine 
administered may also be sequestered by circulating white blood cells (WBC) and 
be actively transported to the inflammatory lesion. 
 Based upon these previous studies, we hypothesized that a macromolecular 
Tofacitinib prodrug would selectively target inflamed joints, followed by sequestra-
tion in resident cells and activation to release Tofa locally to suppress joint inflam-
mation.  Our initial attempt to conjugate Tofa to HPMA copolymer was challenging.  
The secondary amine in the pyrrole ring is the only available site for chemical con-
jugation.  Given the regional pyrrole/pyrimidine-conjugation, this amine is not very 
reactive.  Attempts to conjugate Tofa to HPMA copolymer via peptides or citraconic 
acid linkers failed.  Eventually, Tofa was successfully conjugated to HEMA via a 
carbamate bond and the Tofa-containing monomer was copolymerized with HPMA 
(Figure 5.1A and 5.1B).  We purposely set the P-Tofa molecular weight (~ 30 kDa) 
lower than the glomerular filtration threshold of 45 kDa of HPMA copolymer to allow 
eventual renal clearance of the prodrug.  There was an initial concern regarding 
the use of a carbamate linker as it has been known to be relatively stable in vivo.  
The in vitro release study (Figure 5.2), however, provided strong evidence that the 
prodrug can be gradually activated under acidic environments (e.g. inflammatory 
acidosis or lysosomal pH).   
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5.5 Conclusion  
 In this study, we have developed a macromolecular prodrug of a Janus Kinase 
(JAK) inhibitor, Tofacitinib (P-Tofa) using a well-established, water-soluble and bi-
ocompatible N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer. 
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CHAPTER 6 
IN VITRO AND IN VIVO EVALUATION OF TOFACITINIB PRODRUG 
THERAPEUTIC EFFICACY AND REDUCTION OF TOXICITY 
6.1 Introduction  
 Rheumatoid arthritis (RA) is a chronic, inflammatory disorder that affects up to 
1% of adults worldwide [176, 177].  The disease often leads to significant pain 
associated with progressive articular damage.  At present, there is no cure for RA 
[9, 178].  The identification of the key role of intracellular kinase signaling pathways 
in the regulation of proinflammatory cytokines and immune cell activation has led 
to the recent development of orally available low molecular weight drugs that se-
lectively target individual members of the Janus kinase pathway [172].   
 As discussed in Chapter 5, we successfully synthesized Tofa prodrug (P-Tofa). 
To further investigate this prodrug, the therapeutic efficacy and potential toxicities 
of P-Tofa were evaluated in an adjuvant-induced arthritis (AA) rat model.   
6.2 Materials and Methods  
6.2.1 Instruments 
 Histology slides were scanned with a VENTANA iScanner HT (Tucson, AZ, 
USA).  Bone quality were analyzed using a Skyscan 1172 high resolution micro-
CT system (Skyscan, Kontich, Belgium).  A Faxitron® MX-20 Cabinet X-ray System 
(Tucson, Arizona, USA) was used to monitor the hard tissue decalcification pro-
gress.  A Leica RM2255 rotary microtome (Leica Biosystems Inc., Buffalo Grove, 
IL, USA) was used for paraffin-embedded tissue sectioning.  Tissue slides were 
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analyzed using a ZEISS LSM 800 confocal microscope (Carl Zeiss Microscopy, 
LLC, Peabody, MA, USA).  Live animals were imaged using Xenogen IVIS® Spec-
trum in vivo imaging system (PerkinElmer Inc., Waltham, MA, USA). 
6.2.2 Treatment of adjuvant-induced arthritis (AA) rats  
 As described previously [146], male Lewis rats (175-200 g) from Charles River 
Laboratories (Wilmington, MA, USA) were used to establish the adjuvant-induced 
arthritis (AA) rat model.  The established AA rats were then divided into 3 groups: 
P-Tofa treatment (n = 10, single i.v. injection on day 14 post-induction, dose equiv-
alent of Tofa = 130.2 mg/kg), Tofa treatment (n=10, Tofa was suspended in 0.5% 
methylcellulose/0.025% Tween 20 (Sigma), once daily oral gavage for 21 days 
from day 14 post-induction, 6.2 mg/kg/day) [179], and saline control (n=8).  An 
additional group (n=5) of healthy rats were used as a negative control.  Joint in-
flammation and body weight were monitored daily from day 11.  Hematology pro-
files including absolute count of white blood cells (WBC), neutrophils (NE), 
lymphocytes (LY), monocytes (MO), eosinophils (EO) and basophils (BA) were 
analyzed using an HEMAVET 950 FS Hematology System (Drew Scientific Inc., 
Miami Lakes, FL, USA) every week post treatment initiation until the last date of 
free Tofa treatment.  Blood was collected for liver enzyme analysis at necropsy.  
Liver function including alanine aminotransferase (ALT), aspartate aminotransfer-
ase (AST), and alkaline phosphatase (ALP) were analyzed using a DTX 880 Mul-
timode Detector (Beckman Coulter, Jersey City, NJ, USA) at UNMC clinical test 
lab.  All major organs were collected at the euthanasia and fixed with buffered 
formalin before paraffin embedding.  Tissue sections (5 μm) were processed and 
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H&E stained for histological evaluation by a pathologist (SML), who was blinded 
to the treatment group arrangement.  All animal experiments were performed in 
accordance with protocols approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of Nebraska Medical Center or Hospital for 
Special Surgery.  
6.2.3 Observational assessment of AA rats’ joint inflammation  
 The articular index (AI) score was recorded during the treatment by the same 
observers (XW and GZ) as described previously [146].  An AI score was given to 
each hind limb from day 11 to day 56 post-arthritis induction.  The AI scoring sys-
tem is based on a 0-4 numeric system as the following: 0 = no signs of swelling or 
erythema; 1 = slight swelling and/or erythema; 2 = low-to-moderate edema and 
signs involving the tarsals; 3 = pronounced edema with limited use of the joint and 
signs extending to the metatarsals; 4 = excessive edema with joint rigidity and 
severe signs involving the entire hind paw.  The sum of the two hind limb scores 
for each animal was recorded.  Ankle diameter (medial to lateral) was measured 
using a digital caliper as confirmation of inflammation-associated edema/hyper-
plasia. 
6.2.4 Micro-CT analysis of articular bone quality  
 Hind limbs were isolated after euthanasia and fixed with buffered formalin for 
no less than 48 hr.  The left ankle joint bone quality was analyzed using a Skyscan 
1172 micro-CT system.  Micro-CT scanning parameters were set as follows: volt-
age, 70 kV; current, 142 μA; exposure time, 3650 ms; resolution, 13.1 μm; with 
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aluminum filter (0.5 mm); rotation step = 0.4; frame averaging = 6; random move-
ment = 10; using 360 rotation scanning.  Raw data were reconstructed using 
NRecon to obtain a visual representation of the results, and the volume rendering 
of the samples were performed via CTvox software (Skyscan).  To quantitatively 
compare the four treatments, the entire calcaneus and the selected region of in-
terest (ROI) of the trabecular bone within the calcaneus (Figure 6.1) were used as 
the anatomical sites for micro-CT analyses.  The ROI was defined by aligning the 
calcaneus bone along the sagittal plane using Dataviewer, with the ROI starts at 
the 75th slide away from the epiphyseal plate and continues for 76 slides (1.98 mm).  
The diameter of the cylindrical ROI was set at 1.00 mm.  The morphometric pa-
rameters, such as percent bone volume (BV/TV), bone surface density (BS/TV), 
trabecular separation (Tb.Sp), trabecular number (Tb.N), bone mineral density 
(BMD), and trabecular thickness (Tb.Th) were calculated using CTAn (Skyscan).   
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Figure 6.1 Region of interest in micro-CT analyses.  Gray color: rat calcaneus bone; 
Red color: cylindrical ROI within the calcaneus bone. 
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6.2.5 Joint tissue histological evaluation 
 Right hind limbs were decalcified using 5% formic acid after fixation for histo-
logical analyses.  Upon complete decalcification, the tissues were paraffin-embed-
ded, sectioned (8 μm) approximately 200 μm apart, then H&E and Safranin O 
stained.  Stained sections were histologically graded by a pathologist (SML), who 
was blinded to treatment groups [146], and then scanned using a high-throughput 
bright-field slide scanner.  Each histopathologic feature was graded as follows: 
synovial cell lining hyperplasia (0 to 2); pannus formation (0 to 3); mononuclear 
cell infiltration (0 to 3); polymorphonuclear leukocytes infiltration in periarticular soft 
tissue (0 to 3); cellular infiltration and bone erosion at the distal tibia (0 to 3); and 
cellular infiltration of cartilage (0 to 2).  Scores for all of the histopathologic features 
were summed for each animal.    
6.2.6 P-Tofa biodistribution  
 P-Tofa was labeled with IRDye® 800CW (P-Tofa-IRDye) and administered i.v. 
to AA rats (n=5) on day 14 post-induction.  Rats were then imaged with a Xenogen 
IVIS® Spectrum in vivo system under anesthesia at designated time points.  The 
images were captured with the following conditions: Excitation: 778 nm (Filter: 745 
nm); Emission: 794 nm (Filter: 800nm); exposure times: 2 s; Field of View: 24.5 
cm; Binning Factor: 8; f Number: 2.  The captured images were then analyzed 
using the Living Image 4.5 software (PerkinElmer Inc.).  For ex vivo organ distri-
bution analyses, P-Tofa-IRDye was administered i.v. to AA rats (n=3 per time point) 
on day 14 post-induction.  Rats were perfused and euthanized at the designated 
time points.  Major organs were then collected and imaged using a Pearl® Impulse 
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small animal imaging system (LI-COR, Lincoln, NE, USA).  The image acquiring 
conditions were set as dual channels (800 nm and white light) with 85 µm resolu-
tion.  The images for each rat were obtained using the same intensity scale with a 
common minimum and maximum value. 
6.2.7 Immunohistochemically analysis of P-Tofa’s cellular uptake within ankle 
joints  
 Alexa Fluor® 647-labeled P-Tofa (P-Tofa-Alexa) was administered i.v. to AA 
rats (n=5) on day 14 post-induction.  Twenty-four hours later, rats were perfused 
and euthanized.  Hind limbs were collected, fixed and decalcified using 14% EDTA 
solution (pH=7.4), paraffin embedded, sectioned (20 µm).  The slides were im-
munohistochemically stained with the following antibodies: mouse anti-rat CD68 
(Bio-Rad, MCA341R, dilution 1:100) and rabbit anti-rat P4HB (Abcam, ab85564, 
dilution 1:50), respectively, overnight at 4 C after antigen retrieval using sodium 
citrate buffer and blocked using 10% normal goat serum.  Slides incubated with 
mouse anti-rat CD68 were further incubated with Alexa Fluor 488-labeled goat 
anti-mouse secondary antibody (Thermo Fisher scientific, A11001, dilution 1:1000) 
and slides incubated with rabbit anti-rat P4HB were incubated with Alexa Fluor 
488-labled goat anti-rabbit secondary antibody (Thermo Fisher scientific, A11008, 
dilution 1:1000) for another 1 hr at 21 C in the dark.  The stained slides were 
imaged using a ZEISS LSM 800 confocal microscope after mounted in ProLong® 
Gold antifade mountant with DAPI (Thermo Fisher scientific, P36931, Waltham, 
MA). 
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6.2.8 In vitro macrophage cell culture.  
 Primary bone marrow macrophages (BMMs) were isolated from 6-8 week old 
C57BL/6 mice [180].  BMMs were treated with Tofa (1 µM) or P-Tofa (Tofa equiv-
alent = 16.1 µM) for 1 hr, after which 0.04 ng/mL, and 0.2 ng/mL of IL-4 was added 
for 24 hr.  For “washout” experiments, a similar procedure was followed, except 
the P-Tofa/Tofa incubation time was increased to 24 hr, following which the cells 
were washed and incubated with fresh medium (without P-Tofa or Tofa) for 72 hr 
or 1 week, prior to the IL-4 challenge.  RNA was isolated using RNAeasy kits (Qi-
agen, Redwood City, CA), in accordance with manufacturer’s recommendations 
and reverse transcribed using the Maxima First Strand cDNA Synthesis Kit for RT-
qPCR (Thermo Scientific, Waltham, MA, USA).  Real-time qPCR was performed 
using the Maxima SYBR Green/Fluorescein qPCR Master Mix 2X (Thermo Scien-
tific, Waltham, MA, USA) on a CFX96 real time thermocycler (Bio-Rad, Hercules, 
CA, USA) and the relative gene expression was measured using the standard 
ΔΔCq method and normalized to mouse GAPDH expression.  Arg1, Ym1/2 and 
Fizz1 and their respective sequences are listed as follows: 
Arg1 (GGAATCTGCATGGGCAACCTGTGT/AGGGTCTACGTCTCGCAAGCCA),  
Ym1/2 (GGGCATACCTTTATCCTGAG/CCACTGAAGTCATCCATGTC),  
Fizz1 (TCCCAGTGAATACTGATGAGA/CCACTCTGGATCTCCCAAGA), 
GAPDH (GGTGCTGAGTATGTCGTGGA/GTGGTTCACACCCATCACAA) 
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6.2.9 Serum cytokine measurements 
 CXCL10 protein levels in rat serum samples collected weekly from day 14 to 
day 56 were quantified by ELISA (Abnova, Rat CXCL10 ELISA Cat #KA2203, Tai-
pei City, Taiwan).  The assay was performed in duplicate using a two-fold dilution 
of serum according to the manufacturer’s instruction. 
6.2.10 Statistical methods 
 One-way analysis of variance (ANOVA), followed by Tukey’s post hoc test to 
account for multiple comparisons, was used for data analysis using GraphPad 
Prism Software.  P-values ≤ 0.05 were considered statistically significant. 
6.3 Results  
6.3.1 P-Tofa provides sustained amelioration of joint inflammation in AA rats. 
 Ankle diameter and AI score of the Tofa-treated group exhibited a continuous 
decrease from day 15 to 34 post-arthritis induction, with an immediate flare upon 
cessation of oral Tofa on day 35 (Figure 6.2).  A single injection of P-Tofa (dose 
equivalent to the entire Tofa treatment) resulted in greater reductions in ankle 
swelling and AI score from day 15 to 34, a difference that persisted to day 56.  The 
ankle diameter of the P-Tofa group was significantly lower (P < 0.05) than both the 
Tofa group and saline group from day 14 to day 56; and significantly higher (P < 
0.05) than the healthy control group from day 11 to day 56.  No significant differ-
ences were found between the Tofa and saline groups except day 16 to day 22.   
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Figure 6.2 P-Tofa can effectively amelioration of joint inflammation in an adjuvant-
induced arthritis (AA) rat model.  (A) The change of AA rats’ left ankle joint size of 
different groups during the treatment study; (B) The change of articular index score 
of different groups during the treatment study.  The arrow pointing up indicates the 
day when rats received the single P-Tofa injection and the daily oral Tofa treatment 
was initiated.  The arrow pointing down indicates the day when rats received their 
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last oral Tofa treatment.  The prevention of arthritic ankle swelling by single injec-
tion of P-Tofa was sustained for 6 weeks from day 15 to day 56. 
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6.3.2 Histological Analysis of the Ankle Joints. 
 Compared to healthy control animals, histological analyses revealed marked 
bone and cartilage destruction of the distal tibia, calcaneus and talus joints in the 
saline-treated group, with periosteal expansion and inflammatory cell infiltration.  
The Tofa-treated group exhibited histological findings similar to the saline group, 
consistent with a limited capacity in preventing joint bone erosion and cartilage 
damage.  The single dose P-Tofa group, however, displayed markedly reduced 
joint damage and cellular infiltration, with bone and cartilage morphology main-
tained similar to that of the healthy rats (Figure 6.3A, 6.3B).  The sum of the score 
from each animal was recorded and shown in Figure 6.3C.  The statistically signif-
icant difference was found between Healthy vs. Saline, Saline vs. P-Tofa and P-
Tofa vs. Tofa groups.  No significant difference was found between P-Tofa vs. 
Healthy or Saline vs. Tofa groups. 
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Figure 6.3 Histology evaluation of Tofa and P-Tofa therapeutic efficacy.  (A) H&E-
stained joint sections (10× and 40×).  Cellular infiltration in periarticular soft tissue, 
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bone and cartilage damage in Tofa and saline groups; (B) Safranin O-stained joint 
sections (10× and 40×). Ta, talus; Ti, tibia; CD, cartilage damage; CI, cell infiltration; 
BD, bone damage; (C) Semi-quantitative comparisons of histology scores of all 
treatment groups (*, P ≤ 0.05, ANOVA).   
  
133 
 
6.3.3 Micro-CT evaluation of joint bone quality 
 The most severe bone damage was found in the saline group, with extensive 
erosion of the entire distal tibia (Figure 6.4A).  Tofa-treated animals demonstrated 
reduced ankle bone erosion compared to the saline group.  Six weeks following 
the single dose P-Tofa administration, there was only minor bone erosion.  The 
quantitative analysis of the hind paw calcaneus trabecular bone (Figure 6.4B) mi-
cro-CT data shows that P-Tofa treatment preserved the bone quality as evident in 
the morphometric parameters, such as percent bone volume (BV/TV), bone sur-
face density (BS/TV), trabecular separation (Tb.Sp), trabecular number (Tb.N), 
bone mineral density (BMD), and trabecular thickness (Tb.Th) with their values 
similar to those observed for healthy controls; and significantly better than those 
observed for free Tofa-treated and the saline control.  When the entire calcaneus 
bone was analyzed (Figure 6.4C), the Tofa and saline groups were found with 
significantly increased calcaneus tissue volume and calcaneus bone surface, and 
significantly decreased calcaneus bone volume percentage, when compared to 
the healthy and P-Tofa-treated groups. 
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Figure 6.4 Micro-CT analyses of the hind paw of the rats from different treatment 
groups.  (A) Representative 3-D reconstructed ankle joints from each treatment 
group.  P-Tofa-treated rats were most similar structurally to the healthy group, 
while saline group exhibited extensive bone erosion. Significant bone damage was 
also found in the Tofa treated animals; (B) Bone morphometric parameters of the 
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red cylinder ROI within calcaneus bone as shown in Figure 6.1; (C) Bone morpho-
metric parameters of the entire calcaneus bone.  No significant difference between 
the healthy and P-Tofa treated rats was found for all the parameters, indicative of 
the potent joint preservation capacity of the single dose P-Tofa treatment. (*, P ≤ 
0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001) 
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6.3.4 Passive targeting and retention of P-Tofa in arthritic joints 
 Near infrared optical imaging analyses revealed that systemically administered 
P-Tofa-IRDye was mainly distributed to arthritic joints (Figure 6.5A).  Signals ob-
served at the ear and the base of the tail were attributed to the trauma from ear 
tag installation and inflammation associated with immunization.  Signal intensity in 
the joints gradually decreased from ~1×109 to ~2×108 (p/sec/cm2/sr)/(uW/cm2) 
over 12-days.  To validate live imaging results, major organs and both hind limbs 
were collected at necropsy and imaged ex vivo.  The inflamed joints, especially the 
hind limb ankle joints, were the major sites of P-Tofa-IRDye distribution with mod-
erate-to-high signal intensity also observed in the liver and kidneys (Figure 6.5B).  
The lack of fluorescent signal observation confirmed the absence of P-Tofa in the 
other organs.  Semi-quantitative analyses of the optical imaging data corroborated 
this observation (Figure 6.5C). 
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Figure 6.5 Near infrared optical imaging-based analysis of P-Tofa biodistribution. 
(A) Representative IVIS images depicting P-Tofa-IRDye biodistribution in AA and 
healthy rats after systemic administration.  Images obtained 1, 4, 7 and 12 days 
after one intravenous injection of P-Tofa-IRDye demonstrate its retention in ar-
thritic joints; (B) Representative ex vivo optical imaging of major organs and limbs 
from AA rats at 1, 3 and 7-day post P-Tofa-IRDye administration; (C) Semi-quan-
titative analyses of P-Tofa-IRDye biodistribution.  P-Tofa-IRDye signals were de-
tected mainly in the arthritic joints, liver and kidneys. 
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6.3.5 Cellular distribution of P-Tofa  
 To identify the cell types that sequestered and retained P-Tofa within the joint, 
immunohistochemistry staining with a series of cell-specific markers was per-
formed.  Numerous P-Tofa-Alexa 647 (red fluorescence) positive cells were found 
in synovial tissues where they co-localized with P4HB+ (fibroblast) and CD68+ 
(monocytes/macrophages) cells, consistent with synoviocyte-mediated subcellular 
sequestration of P-Tofa-Alexa 647 (Figure 6.6). 
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Figure 6.6 Representative confocal microscopy of anti-CD68 and anti-P4HB anti-
body stained sections of decalcified ankle joints from AA rates following systemic 
administration of P-Tofa-Alexa.  Each panel is composed of five subpanels: Anti-
body signal (green), P-Tofa-Alexa signal (red), DAPI signal (blue), a merged image 
at 200× magnification and a merged image at 630× magnification are shown. Co-
localization of the red and green colors confirmed the internalization of the P–Tofa-
Alexa by P4HB+ (fibroblast) and CD68+ (monocytes/macrophages) synoviocytes 
in the arthritic joints. White arrow points to the sites of colocalization. 
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6.3.6 In vitro inhibition of JAK/STAT signaling by P-Tofa and Tofa. 
 To assess the ability of P-Tofa and Tofa to inhibit JAK/STAT signaling, primary 
murine BMM were treated with or without P-Tofa or Tofa for 1 hr or 24 hr, then 
challenged with 2 different IL-4 concentrations (0.2 ng/mL and 0.04 ng/mL).  qPCR 
analysis revealed that, as expected, IL-4 strongly induced expression of alternative 
macrophage activation markers Arg1, Ym1/2 and Fizz1, and both Tofa and P-Tofa 
pretreatment for 24 hr (Figure 6.7A) or 1 hr (not shown) effectively repressed in-
duction of all three genes.  To evaluate if P-Tofa offers sustained anti-inflammatory 
activity, cells were pretreated with P-Tofa or Tofa, then washed and cultured for 
an additional 72 hr in the absence of the inhibitors, prior to IL-4 challenge.  Notably, 
under these conditions, P-Tofa retained the ability to repress IL-4 signaling to a 
significantly greater extent than free Tofa (Figure 6.7B), suggesting that P-Tofa 
provides sustained efficacy via its cellular sequestration and subsequent subcellu-
lar Tofa release.   
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Figure 6.7 qPCR analyses of expression of Arg1, Ym1/2 and Fizz1 from BMMs 
after treatment with IL-4.  (A) Expression levels of IL4-induced genes after 24 hr 
Tofa or P-Tofa treatment; (B) Expression levels of IL4-induced genes after 24 hr 
Tofa or P-Tofa treatment, inhibitor washout and 72 hr additional culture without the 
inhibitors. (*, P < 0.05 versus no drug at same level of IL-4; ^, P < 0.05 versus Tofa 
at same level of IL-4) 
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6.3.7 The impact of Tofa and P-Tofa treatments on serum levels of CXCL 10 
 To evaluate the effects of Tofa and P-Tofa treatments on systemic inflamma-
tory cytokines, serum levels of CXCL10 were evaluated.  As shown in Figure 6.8, 
CXCL10 levels were significantly elevated in arthritic rats at day 35 post arthritis 
induction, when compared to the healthy controls.  A single dose of P-Tofa com-
pletely normalized the CXCL10 levels.  Daily Tofa treatments also significantly de-
creased serum CXCL10 levels, though the levels were significantly higher 
compared to the P-Tofa group. 
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Figure 6.8 Serum CXCL10 levels at days 35 from different groups of rats. (*, P ≤ 
0.05; ****, P ≤ 0.0001) 
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6.3.8 Preliminary toxicity assessment 
 Under the present dosing level, hematologic profiles of P-Tofa and Tofa treated 
animals (Table 6.1) were similar until week 3, when significantly lower total white 
blood cells (WBC), neutrophils (NE), eosinophils (EO) and basophils (BA) were 
observed in P-Tofa group.  A small but significantly lower alkaline phosphatase 
(ALP) value was found in the P-Tofa group compared to the Tofa group at nec-
ropsy.  There were no differences in AST or ALT levels.  No histological abnormity 
(not shown) was found in major organs from P-Tofa group by the pathologist (SML) 
who was blinded to the group arrangement.   
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  P-Tofa Tofa 
  CBC 
  1 week 2 weeks 3 weeks 1 week 2 weeks 3 weeks 
WBC 
(K/µL) 
22.1 ± 6.1 14.9 ± 3.3 10.2 ± 2.7* 24.6 ± 8.0 17.3 ± 5.9 19.1 ± 5.0 
NE 
(K/µL) 
8.3 ± 3.0 5.0 ± 2.0  1.8 ± 1.7* 11.0 ± 3.5 6.4 ± 4.1 7.7 ± 3.3 
LY 
(K/µL) 
11.9 ± 3.0 7.7 ± 1.2 6.3 ± 2.0 12.0 ± 4.0 9.0 ± 3.3 9.9 ± 2.4 
MO 
(K/µL) 
0.6 ± 0.3 1.2 ± 0.5 0.8 ± 0.5 0.7 ± 0.4 1.0 ± 0.4 0.6 ± 0.3 
EO 
(K/µL) 
0.8 ± 0.6 0.6 ± 0.2 0.1 ± 0.1* 0.7 ± 0.5 0.7 ± 0.4 0.6 ± 0.2 
BA 
(K/µL) 
0.3 ± 0.3 0.3 ± 0.1 
0.04 ± 
0.04* 
0.3 ± 0.2 0.3 ± 0.2 0.3 ± 0.1 
  Liver Function at Necropsy 
AST 
(U/L) 
69.5 ± 2.0 67.6 ± 2.4 
ALT 
(U/L) 
76.3 ± 4.7  76.6 ± 2.7 
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ALP 
(U/L) 
315.3 ± 29.4* 347.3 ± 23.4 
Table 6.1 Hematologic profiles and liver function tests with P-Tofa and Tofa treat-
ments. *, P≤0.05, significantly lower than Tofa group 
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6.4 Discussion  
 To test our hypothesis, a HPMA copolymer-based macromolecular prodrug of 
Tofacitinib (P-Tofa) was designed, synthesized and evaluated using an adjuvant-
induced arthritis rat model.  To establish the arthrotropism of P-Tofa according to 
our hypothesis, rats with established AA were administered P-Tofa-IRDye and its 
biodistribution and tissue-specific retention were evaluated using sequential in vivo 
NIR optical imaging.  As shown in Figure 6.5A, the IRDye signal mainly localized 
in the arthritic limbs.  Due to the limited tissue penetration depth of the NIR fluo-
rescent signal [181], the distribution of P-Tofa-IRDye in the major organs and ar-
thritic limbs were imaged ex vivo and analyzed semi-quantitatively using an LI-
COR small animal imager.  The results (Figure 6.5B, 6.5C) confirmed that the in-
flamed joints in the affected limbs were the major sites of P-Tofa-IRDye localization 
with additional distribution sites in the main clearance organs (i.e. liver and kid-
neys).  On a cellular level, immunohistochemistry analysis of the decalcified ar-
thritic joints revealed that the P-Tofa-Alexa was sequestered by fibroblast-like 
(P4HB+) and macrophage-like (CD68+) synoviocytes (Figure 6.6), providing direct 
evidence of P-Tofa’s targeting to key cell types involved in the joint inflammatory 
pathology [182-184].   
 We hypothesized that the tissue and cellular specificity of systemically admin-
istered P-Tofa would lead to a potent and sustained anti-rheumatic effect.  Our 
original dose equivalent treatment protocol was designed to terminate at day 35 
post arthritis induction.  The results (Figure 6.2A, 6.2B) established that a single 
dose of P-Tofa was effective in ameliorating joint inflammation and improving the 
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articular index (AI) scores during this period of time.  Having observed this initial 
beneficial effect, we further extended the observation period.  To maintain dose 
equivalence, no additional Tofa was given to the Tofa group.  Of importance, the 
single dose P-Tofa treated rats continued to show reduced joint inflammation and 
articular index score reduction until day 65 post arthritis induction, when signs of a 
minor arthritis flare (e.g. a small increase of the arthritis score) was observed.  Im-
mediately after the cessation of Tofa treatment, a flare was detected in the Tofa 
treated group, which continued to worsen until the experimental endpoint (day 65 
post arthritis induction).  Tissue histopathology (Figure 6.3A, 6.3B) and micro-CT 
(Figure 6.4) analyses of the ankle joints isolated at the end point of the experiment 
demonstrated preservation of joint cartilage and subchondral bone integrity in the 
animals treated with the single dose P-Tofa.  The Tofa-treated animals, in contrast, 
showed only moderate bone and cartilage protection when compared to the saline 
controls; but exhibited more extensive joint tissue damage compared to the P-
Tofa-treated group.  
 In vitro cell culture studies were undertaken to compare the efficacy of P-Tofa 
and Tofa in inhibition of JAK/STAT signaling.  Murine BMM were treated with P-
Tofa or Tofa prior to challenge with IL-4.  This cytokine signals via the JAK/STAT6 
pathway and induces the expression of markers of alternative macrophage activa-
tion, including arginase-1 (Arg1), YM1/2, and Fizz1.  qPCR analysis revealed that 
IL-4 strongly induced expression of Arg1, Ym1/2 and Fizz1.  Tofa treatment for 24 
hr or 1 hr effectively repressed induction of all three genes.  P-Tofa was equally 
effective under these conditions (Figure 6.7A).  To assess the relative efficacy of 
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P-Tofa or Tofa to produce sustained inhibition of IL-4 induced JAK/STAT signaling, 
in a second set of experiments, cells were pretreated with P-Tofa or Tofa, then 
washed and cultured for an additional 72 hr in the absence of inhibitors, prior to IL-
4 challenge.  Of importance, under these conditions, the P-Tofa treatment pro-
duced sustained inhibition of IL-4 signaling (Figure 6.7B), whereas the Tofa treated 
cells became IL-4 responsive by 72 hr.  These findings are consistent with sus-
tained release of active drug from the P-Tofa and corroborate well with the in vitro 
data (Figure 6.2) showing the sustained release of free Tofa in acidic environments, 
present in the synovium of patients with active arthritis and in the subcellular lyso-
somal compartment in which the macromolecular prodrug is sequestered [175]. 
 To further explore the impact of P-Tofa treatment, we measured the serum lev-
els of CXCL10.  In human studies, circulating CXCL10 as well as synovial expres-
sion of this chemokine has been shown to be sensitive to Tofa treatment [185] and 
it has been implicated as a major contributor to the recruitment and activation of 
immune cells involved in the local synovial inflammation.  In this study, we found 
that CXCL10 levels were significantly elevated in arthritic rats, when compared to 
the healthy controls; and a single dose of P-Tofa completely suppressed the ele-
vated serum CXCL10 levels at day 35 post induction of arthritis (Figure 6.8).   
 Our data attributes this superior and long-lasting therapeutic efficacy of P-Tofa 
to its passive targeting to sites of joint inflammation and synoviocyte-mediated lo-
cal sequestration and sustained Tofa release, which is distinctively different from 
Tofa’s pharmacokinetic profile [186].  We did detect alterations in WBC count and 
ALP levels in the P-Tofa group in the later stage of the treatment, suggesting P-
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Tofa dosing at this level (130.2 mg/kg, Tofa equivalent, i.v. single dose) may have 
reached the upper limit of its therapeutic window, which is 20-times higher than the 
Tofa dose (6.2 mg/kg, daily oral gavage) used in a preclinical therapeutic efficacy 
study in this particular animal model [187].  Clearly, additional dose escalation and 
a more comprehensive toxicity studies are necessary to further advance P-Tofa’s 
development.  Given its superior and sustained therapeutic efficacy, we postulate 
that P-Tofa has significant potential for development as a treatment for RA.  
6.5 Conclusion  
 A single i.v. administration of P-Tofa provided superior and sustained thera-
peutic efficacy in an adjuvant-induced arthritis rat model, when compared to dose 
equivalent daily Tofa treatment.  P-Tofa’s significantly widened therapeutic window 
holds the promise for enhancing the clinical efficacy of Tofacitinib for the treatment 
of RA. 
 
  
151 
 
CHAPTER 7 
SUMMARY 
7.1 Conclusion 
 Our laboratory has developed HPMA macromolecular conjugates for early di-
agnosis and better treatment of the musculoskeletal disorders.  The achievement 
we obtained proved our concept hypothesis that the macromolecular prodrug de-
livery system may improve the therapeutic outcome and benefit with the diagnos-
tics targeting.  In my PhD program of study, I focused on the investigation of the 
impacts of the different macromolecular conjugates’ structure parameters on their 
pharmacokinetics, biodistribution and therapeutic efficacy.  A series of the conju-
gates with different molecular weight (MW), drug content, drug-activation mecha-
nism and drug payload were synthesized for this comprehensive investigation.  
The labeled conjugates (conjugates with different MW and drug content) were an-
alyzed for their PK/BD profiles in the murine implant loosening model and in vitro 
cell culture study.  The conjugates with different activation mechanisms were stud-
ied for their in vitro releasing kinetics under different condition (different pH values 
or with human or rat serum) and in vivo therapeutic efficacy in an adjuvant-induced 
arthritis rat model.  Our initial model drug for the above studies is a potent gluco-
corticoid (dexamethasone).  To understand if the development of macromolecular 
prodrug conjugates may also be beneficial for other drug classes, we designed 
and synthesized the HPMA copolymer conjugate (P-Tofa) with a disease-modify-
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ing-antirheumatic drug (tofacitinib, Tofa).  The positive outcome validated our no-
tion that macromolecularization of antirheumatic drug may potneitate the efficacy 
of the parent drug and potentially reduce associated systemic toxicities.  
7.2 Future plan 
 Overall, this project has provided deep insights of the HPMA copolymer conju-
gates’ structure properties’ influence on its efficacy and safety.  These information 
provides further instruction on the rational design of drug delivery systems for the 
clinical management of musculoskeletal conditions.  In the future, other polymeric 
carrier system and drug classes may also be explored for the improved treatment 
of musculoskeletal diseases.  Besides passive targeting, different active targeting 
moieties, including bone targeting ligands may be introduced to further potentiate 
macromolecular prodrug development for better treatment of musculoskeletal dis-
eases. 
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